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ABSTRACT 
Angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) 
use prior to major surgery is controversial. We performed a population based 
retrospective cohort study of 237,208 elderly patients (of whom 101,494 (42.8%) were 
ACEi or ARB users) who underwent major elective surgery from 1995 to 2010 in 
Ontario, Canada. The primary outcome was acute kidney injury treated with dialysis 
(AKI-D) within 14 days following surgery (810 (0.34%) patients). The secondary 
outcome was all-cause mortality within 90 days following surgery (11,089 (4.67%) 
patients). After adjusting for potential confounders, preoperative ACEi or ARB use was 
associated with a lower relative risk of AKI-D (adjusted relative risk (RR): 0.83; 95% 
confidence interval (CI): 0.71 to 0.98) and a lower relative risk of all-cause mortality 
(adjusted RR: 0.91; 95% CI: 0.87 to 0.95). Results were consistent in propensity score 
matched analyses. We observed a significant effect modification by chronic kidney 
disease on AKI-D (p-value < 0.0001). Randomized controlled trials are needed to clarify 
this issue. 
Keywords: Angiotensin converting enzyme inhibitor, angiotensin receptor blocker, acute 
kidney injury treated with dialysis, retrospective cohort study, elective surgery, all-cause 
mortality, relative risk, propensity score matched analyses, chronic kidney disease, 
randomized controlled trials 
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CHAPTER 1 – INTRODUCTION  
 
1.1 Acute Kidney Injury 
Acute kidney injury (AKI) is sudden decline in renal function and severe AKI can require 
treatment with dialysis.1-5 Hospital admission with AKI is associated with a longer 
hospital length of stay and a higher risk of mortality.6;7 In the United States, AKI 
accounts for yearly health care expenditures in excess of ten billion dollars.6 
1.2 Major surgeries can be complicated by acute kidney injury treated with dialysis 
Approximately 1.25 million patients undergo cardiac surgery around the world every 
year.8 About 1% of patients (12,500 patients) develop AKI treated with dialysis (AKI-
D).2;3;8;9 Approximately 225 million patients undergo non-cardiac surgery worldwide 
every year.10 The risk of AKI-D in non-cardiac surgeries is particularly high with 
vascular, thoracic, abdominal, and retro-peritoneal surgeries.4;11-14 About 0.4% of patients 
(900,000 patients) undergoing non-cardiac surgery develop AKI-D.15-17 
Postoperative AKI occurs as a result of decreased renal perfusion which causes a hypoxic 
insult, followed by activation of inflammatory mediators, proinflammatory transcription 
factors, and adhesion molecules which subsequently lead to AKI (Figure 1 and Figure 
2).18;19 There are several clinical factors that may influence a patient’s risk for developing 
postoperative AKI. Chronic kidney disease is considered to be the most important risk 
factor, while other comorbidities such as congestive heart failure, coronary artery disease, 
hypertension, and diabetes may also increase the risk of postoperative AKI.11;13;20 
Perioperative clinical factors such as hypotension, blood loss, volume depletion, and 
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administration of vasoconstrictor agents may all increase the risk of postoperative 
AKI.19;21  
Some preoperative medications may also influence the risk of postoperative AKI.17 This 
is particular true for angiotensin converting enzyme inhibitor (ACEi) and angiotensin 
receptor blocker (ARB), which is the focus of this dissertation given the possibility of 
modification prior to planned elective surgeries.12;21-28  
1.3 Angiotensin converting enzyme inhibitor and angiotensin receptor blocker  
ACEi and ARB are therapeutic drug classes that inhibit the renin-angiotensin 
system.25;29;30 ACEi inhibits angiotensin converting enzyme primarily formed in the 
pulmonary vasculature and prevents formation of angiotensin II from angiotensin I.25 
ARB competitively replace angiotensin II from the angiotensin I receptor and prevents 
angiotensin II mediated effects.30 ACEi was first introduced in 1981 for the treatment of 
hypertension.25 Since then, ACEi has proven to be beneficial in a variety of clinical 
conditions.25 Chronic ACEi and ARB use in the outpatient settings reduces the risk of 
mortality, stroke, and myocardial infarction (fatal and non-fatal).25;30 Patients with 
comorbid conditions such as congestive heart failure, atherosclerotic cardiovascular 
disease, diabetes mellitus, and chronic kidney disease benefit from using ACEi and ARB 
medications.25;29;31 Several international randomized controlled trials such as HOPE, 
EUROPA, PEACE, OPTIMAAL, VALIANT, and SAVE trials have also demonstrated 
benefits of ACEi and ARB use in reducing cardiovascular morbidity and mortality.32-38 
Due to these benefits, ACEi and ARB are highly prescribed medications: in the United 
States there are more than 155 million prescriptions filled each year for ACEi and more 
than 80 million prescriptions for ARB.39  
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1.4 Impact of preoperative ACEi or ARB use on renal function 
ACEi or ARB use lowers blood pressure.25;30 Preoperative use of these medications may 
exacerbate hypotension from anesthesia and may lead to renal hypoperfusion 
(Figure 1).26;29;40-43 Perioperative clinical factors such as poor cardiac output, blood loss, 
dehydration, and administration of vasoconstrictors can all contribute to lower renal 
perfusion.19;21;44 The autoregulation to renal hypoperfusion is to increase angiotensin II 
production, which constricts the glomerular efferent arteriole and maintains the 
glomerular filtration rate (GFR).44 However, ACEi or ARB use interferes with the 
angiotensin II mediated autoregulation to renal hypoperfusion.19;44 This can lead to 
sudden decline in GFR, hypoxic insult, followed by activation of the inflammatory 
response, and subsequent AKI (Figure 1).18;19;44  
Contrary to the proposed damaging effects, ACEi or ARB use may have beneficial 
effects which reduce the risk of postoperative AKI (Figure 2).23;25;29;30;45-50 ACEi and 
ARB medications possess vasculoprotective properties mainly through inhibition of a 
potent vasoconstrictor, angiotensin II.23;25;29;30;45-50 Angiotensin II can increase the risk of 
postoperative AKI by accelerating oxidative stress, endothelial dysfunction, the 
inflammatory response, and acute ischemia, which may be mitigated by ACEi or ARB 
use.23;25;29;30;46-48 ACEi or ARB use through the inhibition of angiotensin II mediated 
vasoconstriction can also reduce the risk of postoperative AKI by decreasing renal 
vascular resistance and promoting renal blood flow.23;25;29;30;45-50  
1.5 Clinical practice guidelines: Preoperative ACEi or ARB use 
There is lack of clear recommendations on whether ACEi or ARB should be withheld 
prior to major surgery with a marked difference in practice patterns 
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worldwide.21;22;40;41;51-53 The American College of Cardiology (ACC) / American Heart 
Association (AHA) 2007 guidelines reported that several authors suggested to withhold 
ACEi or ARB medication the morning of surgery and to restart these medications in the 
postoperative period only when a patient is euvolemic.52 This management strategy may 
reduce the risk of postoperative AKI but there is lack of high quality evidence to support 
this suggestion.52  
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Figure 1: Preoperative ACEi or ARB use may lead to AKI
18;19;26;29;40-44;54-58
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
ACEi: Angiotensin converting enzyme inhibitor; ARB: Angiotensin receptor blocker;  
AKI: Acute kidney injury; GFR: Glomerular filtration rate; 
This figure is partly adapted from Rosner et al.19 
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Figure 2: Preoperative ACEi or ARB use may prevent AKI
18;19;23;25;28;46-50;54-58
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
ACEi: Angiotensin converting enzyme inhibitor; ARB: Angiotensin receptor blocker; AKI: Acute kidney 
injury; GFR: Glomerular filtration rate 
This figure is partly adapted from Rosner et al.19 
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CHAPTER 2 – LITERATURE REVIEW 
 
2.1 Potential risk factors for postoperative AKI 
We performed a literature review to identify potential risk factors for postoperative AKI 
(requiring or not requiring dialysis).4;9;11;13;17;20 We summarized the potential risk factors 
and their association with postoperative AKI in Table 1. Thakar et al.9, in a predictive 
model for AKI after cardiac surgery, suggested that congestive heart failure, diabetes 
mellitus, chronic obstructive pulmonary disease, peripheral vascular disease, and 
cerebrovascular disease were potential risk factors for postoperative AKI-D. Kheterpal et 
al.
13, in a risk index for AKI after general surgery, indicated that older age (≥ 56 years), 
male sex, diabetes mellitus, chronic kidney disease, congestive heart failure, 
hypertension, and intraperitoneal surgery were all potential risk factors for postoperative 
AKI.  
2.2 Present studies: Preoperative ACEi or ARB use and AKI 
As of May 2012, 12 observational studies (11 published studies and one abstract)  have 
examined the association between preoperative ACEi or ARB use and postoperative AKI 
with non-users as the comparison group.12;21-24;26-28;49;50;59;60 Four studies described a 
higher risk of AKI with preoperative ACEi or ARB use 12;21;22;60, while six studies 
described no significant association.26-28;49;50;59 Conversely, two studies suggested a lower 
risk of AKI with preoperative ACEi or ARB use.23;24 We summarized all 12 studies in 
Table 2, 3, and 4.12;21-24;26-28;49;50;59;60 In Table 5 we also summarized key baseline 
characteristics that differed in ACEi or ARB users and non-users in studies of 
postoperative AKI.21-24;26;28;49 Characteristics such as congestive heart failure, diabetes 
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mellitus, hypertension, coronary artery disease, chronic kidney disease, and peripheral 
vascular disease were more in ACEi or ARB users compared to non-users.21-24;26;28;49 
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Table 1: Independent risk factors for postoperative AKI 
Risk factors Author Association with postoperative AKI 
(requiring or not requiring dialysis) 
Older age Kheterpal et al.4 Age ≥ 59 years: Adjusted hazard ratio = 4.2  
(95% CI: 2.9 to 6.0)  
[Reference group: age < 59 years] 
Kheterpal et al.13 Age ≥ 56 years:  
Adjusted hazard ratio = 1.7  
(95% CI: 1.4 to 2.2)  
[Reference group: age < 56 years]   
Abelha et al.11 Age ≥ 65 years: OR = 1.9  
(95% CI: 1.2 to 3.0)  
[Reference group: age < 65 years] 
Male gender Kheterpal et al.13 Adjusted hazard ratio = 1.4  
(95% CI: 1.2 to 1.7) 
Chronic kidney 
disease 
Kheterpal et al.13 Chronic kidney disease (Moderate)+: 
Adjusted hazard ratio = 3.2  
(95% CI: 2.8 to 3.7) 
 
Chronic kidney disease (Mild)*:  
Adjusted hazard ratio = 3.1  
(95% CI: 2.5 to 3.9) 
 
Reference group:  
Patients without chronic kidney disease 
Wijeysundera et al.20 sCr > 133 µmol/L:  
Adjusted OR = 15.2 (95% CI: 9.6 to 24.7) 
 
100 µmol/L < sCr ≤ 133 µmol/L:  
Adjusted OR = 3.1 (95% CI: 1.9 to 5.2)  
 
sCr ≤ 100 µmol/L and CrCl ≤ 60 ml/min: 
Adjusted OR = 2.8 (95% CI: 1.4 to 5.3)  
 
Reference group:  
sCr ≤ 100 µmol/L and CrCl > 60 ml/min 
Hypertension Kheterpal et al.13 Adjusted hazard ratio = 1.5  
(95% CI: 1.2 to 1.9) 
Diabetes – 
Insulin therapy 
Kheterpal et al.13 Adjusted hazard ratio = 1.7  
(95% CI: 1.3 to 2.3)  
Diabetes – Oral 
therapy 
Kheterpal et al.13 Adjusted hazard ratio*” = 1.3  
(95% CI: 1.0 to 1.7)   
Diabetes – 
requiring 
medication 
Wijeysundera et al.20 Adjusted OR = 2.5  
(95% CI: 1.7 to 3.6)  
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Congestive heart 
failure 
Kheterpal et al.13 Adjusted hazard ratio = 2.0  
(95% CI: 1.4 to 3.0)  
Abelha et al.11 OR = 3.9 (95% CI: 2.5 to 6.1)  
Coronary artery 
disease including 
angina 
Abelha et al.11 OR = 2.1 (95% CI: 1.3 to 3.3)  
Peripheral 
vascular disease 
Kheterpal et al.4 Adjusted hazard ratio = 4.2  
(95% CI: 2.5 to 7.1)  
COPD requiring 
treatment with 
bronchodilator 
therapy 
Kheterpal et al.4 Adjusted hazard ratio = 3.0  
(95% CI: 1.9 to 5.0)  
Liver disease Kheterpal et al.4 Adjusted hazard ratio = 2.4  
(95% CI: 1.4 to 4.3)  
Type of surgery Kheterpal et al.4 High-risk surgery++:  
Adjusted hazard ratio = 2.9  
(95% CI: 2.0 to 4.3)  
Kheterpal et al.13 High-risk surgery*+:  
Adjusted hazard ratio = 3.3  
(95% CI: 2.4 to 4.7)   
Abelha et al.11 High-risk surgery#: OR = 3.5  
(95% CI: 2.1 to 5.6) 
 
CI: Confidence interval; OR: Odds ratio; AKI: Acute kidney injury; sCr: Serum creatinine; 
CrCl: Creatinine clearance; COPD: Chronic obstructive pulmonary disease; AKI-D: AKI treated with 
dialysis 
 
Kheterpal et al.13 studied general surgery procedures in adult patients. Postoperative AKI was defined as an 
increase in serum creatinine of  ≥ 2 mg/dl or requirement of dialysis within 30 days after surgery.13 
Preoperative mild* chronic kidney disease was defined as a serum creatinine of 1.2 to 1.9 mg/dl in the 90 
days prior to surgery.13 Preoperative moderate+ chronic kidney disease was defined as a serum creatinine ≥ 
2.0 mg/dl in the 90 days prior to surgery.13 High-risk surgery*+ included intraperitoneal surgery except 
hernia repairs, while the reference group included general surgery involving hernia repairs.13 The adjusted 
hazard ratio*” for diabetes – oral therapy was statistically significant.13 
 
Abelha et al.11 studied major noncardiac surgery in adult patients. AKI was defined according to AKIN 
criteria.5;11 High-risk surgeries# included intrathoracic, intraperitoneal, and suprainguinal vascular 
procedures, while the reference group included the remaining types of major noncardiac surgery.11  
 
Wijeysundera et al.20 studied cardiac surgery procedures in adult patients to identify independent risk 
factors for postoperative AKI-D.  
 
Kheterpal et al.4 studied major noncardiac surgery procedures in adult patients with preoperative CrCl ≥ 80 
ml/min. Postoperative AKI was defined as a CrCl ≤ 50 ml/min within seven days after surgery.4 High-risk 
surgeries++ included intraperitoneal, intrathoracic, suprainguinal vascular, or surgeries involving heavy 
blood loss or fluid resuscitation, while reference group included remaining types of major noncardiac 
surgery.4  
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Table 2: Studies: Preoperative ACEi or ARB use associated with more AKI  
Author Study Design, Setting and Patient 
Groups 
Key Results Conclusions Study 
Limitations 
Cittanova et al.12 
 
 
Prospective cohort study 
249 patients who underwent aortic 
surgery over a 2 year period 
23% (57 out of 249) patients were on 
ACEi 
24.5% (61 out of 249) patients 
developed AKI 
ACEi use was 
significantly associated 
with AKIa:  
Adjusted OR = 2.01;  
95% CI: 1.05 to 3.83,  
p = 0.034 
Preoperative ACEi 
use may increase 
the risk of AKI 
after aortic surgery 
Single centre 
study 
Only studied 
aortic surgery 
Risk of  
overfitting in 
statistical model 
Arora et al.22 
 
  
Retrospective cohort study 
1,358 patients who underwent cardiac 
surgery between 2001 and 2005  
52% (706 out of 1,358) patients were 
on ACEi or ARB   
14% (189 out of 1,358) patients 
developed AKI 
ACEi or ARB users vs. 
non-users (referent): 
AKIb:  
Adjusted OR = 1.41; 
95% CI: 1.07 to 1.85 
Preoperative ACEi 
or ARB use may 
increase the risk of 
AKI after cardiac 
surgery 
Two study 
centres  
Only studied 
cardiac surgery 
 
Miceli et al.21 
 
 
Retrospective cohort study 
9,274 patients who underwent cardiac 
surgery between 1996 and 2008 
51% (4,730 out of 9,274) patients 
were on ACEi or ARB 
Propensity score matched analysis  
3,052 ACEi or ARB users were 
ACEi or ARB users vs. 
non-users (referent): 
 
AKIc (7.1% vs. 5.4%;  
OR = 1.36; 
95% CI: 1.10 to 1.67;  
p = 0.006) 
 
Deathd (1.3% vs. 0.7%; 
Preoperative ACEi 
or ARB use may 
increase the risk of 
AKI and mortality 
after cardiac 
surgery 
Single centre 
study 
Only studied 
cardiac surgery 
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matched to 3,052 non-users OR = 2.00;  
95% CI: 1.17 to 3.42;  
p = 0.013) 
Railton et al.60 Retrospective cohort study 
883 patients who underwent open 
abdominal aortic aneurysm (AAA) 
repair between 1998 and 2005 
41% (366 out of 883) patients were on 
ACEi or ARB  
Propensity score matched analysis 
261 ACEi or ARB users were matched 
to 261 non-users 
ACEi or ARB users vs. 
non-users (referent):  
AKI-De: 4.6% vs. 
0.8%, p = 0.013 
 
Deathf: 6.1% vs. 1.5%; 
OR = 5.00;  
95% CI: 1.40 to 27.00; 
p = 0.008 
Preoperative ACEi 
or ARB use may 
increase the risk of 
AKI-D and 
mortality after open 
abdominal aortic 
aneurysm repair 
Two study 
centres  
Small sample 
size 
Only studied 
open abdominal 
aortic aneurysm 
repair 
 
OR: Odds ratio; CI: Confidence interval; AKI: Acute kidney injury; ACEi: Angiotensin converting enzyme inhibitor; ARB: Angiotensin receptor blocker; 
ESRD: End stage renal disease; AKI-D: AKI treated with dialysis 
 
AKIa was defined as a >20% decrease in creatinine clearance between preoperative and postoperative period. 
AKIb was defined as an increase in serum creatinine > 0.3 mg/dl or > 50% increase from preoperative baseline value according to the RIFLE (risk, injury, failure, 
loss, ESRD) classification.1 
AKIc was defined as a postoperative serum creatinine level > 200 µmol/L and ≥ 1.5 times increase from preoperative baseline serum creatinine value. Deathd 
occurred within 30 days after surgery. 
AKIe was defined as a requirement of dialysis (AKI-D). Deathf occurred within 30 days after surgery. Railton et al.60 did not find a significant association 
between preoperative ACEi or ARB use and AKI (not requiring dialysis) (undefined). 
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Table 3: Studies: Preoperative ACEi or ARB use not associated with AKI 
 
Author Study Design, Setting and 
Patient Groups 
Key Results Conclusions Study 
Limitations 
Ouzounian et al.49 Retrospective cohort study 
 
5,946 patients who underwent 
cardiac surgery between 1998 and 
2007 
 
54.9% (3,262 out of 5,946) 
patients were on ACEi  
 
*1,647 patients were selected to 
study the association with AKI 
ACEi users vs. non-users 
(referent): 
AKIj: Adjusted OR = 0.70; 
95% CI: 0.50 to 1.10;  
p = 0.09 
 
Deathk:  
Adjusted OR = 1.10;  
95% CI: 0.80 to 1.40;  
p = 0.76 
Preoperative ACEi 
use may not be 
associated with 
AKI and mortality 
after cardiac 
surgery 
Single centre 
study 
Only studied 
cardiac surgery 
Risk of 
overfitting in 
statistical model 
for AKI 
Rady et al.50 Retrospective cohort study 
 
11,330 patients who underwent 
cardiac surgery between 1993 and 
1996 
 
26.7% (3,025 out of 11,330) 
patients were on ACEi 
ACEi users vs. non-users 
(referent): 
AKIl: Adjusted OR = 0.90; 
95% CI: 0.70 to 1.20 
Deathm:  
Adjusted OR = 0.90; 
95% CI: 0.70 to 1.20 
ACEi use prior to 
surgery may not be 
associated with 
AKI and mortality 
after cardiac 
surgery 
Single centre 
study 
Only studied 
cardiac surgery 
 
Yoo et al.28 
 
 
Retrospective cohort study 
 
472 patients who underwent 
cardiac surgery between 2006 and 
2009 
62.7% (296 out of 472) patients 
were on ACEi or ARB 
ACEi or ARB users vs. non-
users (referent): 
AKIn:  
Adjusted OR = 0.34;  
95% CI: 0.11 to 1.10;  
p = 0.090 
 
Preoperative ACEi 
or ARB use may 
not be associated 
with AKI after 
cardiac surgery 
Single centre 
study 
Only studied 
cardiac surgery 
Risk of 
overfitting in 
statistical model 
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20.6% (97 out of 472) patients 
developed AKI and 1.5% (7 out of 
472) patients required AKI-D 
 
 
Barodka et al.59  
(Abstract) 
 
 
Retrospective cohort study 
 
6,679 patients who underwent 
cardiac surgery between 1994 and 
2007 
32.4% (2,164 out of 6,679) 
patients were on ACEi 
36.6% (2,447 out of 6,679) 
patients developed AKI 
ACEi users vs. non-users 
(referent): 
AKIo:  
Adjusted OR = 0.97;  
95% CI: 0.88 to 1.07;  
p = 0.52 
 
Preoperative ACEi 
use may not be 
associated with 
AKI after cardiac 
surgery 
Single centre 
study 
Only included 
cardiac surgery 
 
Kheterpal et al.26 
 
  
Prospective cohort study 
 
45,291 patients who underwent 
non-cardiac surgery between 2003 
and 2006 
 
20.2% (9,143 out of 45,291) 
patients were on ACEi or ARB 
Propensity score matched analysis  
Of the matched cohort, 3,256 
patients were selected to study the 
association with AKI 
ACEi or ARB users vs. non-
users (referent):  
AKIi: 1.95% (25/1284) vs.  
1.57% (31/1972), p = 0.51 
 
Preoperative ACEi 
or ARB use may 
not be associated 
with AKI after 
non-cardiac 
surgery 
Single centre 
study 
 
Kincaid et al.27 
 
 
Retrospective cohort study 
 
1,209 patients who underwent 
cardiac surgery between 2000 and 
Preoperative ACEi use 
along with intraoperative 
aprotinin use was 
significantly associated with 
Preoperative ACEi 
use alone was not 
significantly 
associated with 
Single centre 
study 
Only included 
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2002  
45.1% (545 out of 1,209) patients 
were on ACEi 
 
3.5% patients developed AKI 
AKIp:  
Adjusted OR = 2.9;  
95% CI: 1.4 to 5.8;  
p < 0.0001 
 
Neither ACEi nor aprotinin 
alone was significantly 
associated with AKIp 
AKI after cardiac 
surgery 
cardiac surgery 
Risk of 
overfitting in 
statistical model 
 
OR: Odds ratio; CI: Confidence interval; AKI: Acute kidney injury; ACEi: Angiotensin converting enzyme inhibitor; ARB: Angiotensin receptor blocker; 
ESRD: End stage renal disease 
AKIj was defined as serum creatinine exceeding 176 µmol/L and > 50% increase from preoperative baseline value. *Only a subgroup of patients (1,647 patients) 
was considered to examine the association between preoperative ACEi use and AKI because there was no information available on AKI in the database prior to 
2004. Deathk  is in-hospital mortality.  
AKIl was defined with one of the following criteria: (1) increase in serum creatinine concentration ≥ 3.8 mg/dL; (2) doubling of preoperative (baseline) serum 
creatinine concentration if preoperative value > 1.9 mg/dL; (3) a requirement of postoperative dialysis. Deathm occurred within 30 days after surgery. 
AKIn was defined as an increase in serum creatinine greater than 0.3 mg/dl or greater than 50% increase from preoperative baseline value (using RIFLE (risk, 
injury, failure, loss, ESRD) classification1). 
 
AKIo was defined as an increase in serum creatinine > 0.3 mg/dl or 1.5 times or higher increase from preoperative baseline value (using RIFLE (risk, injury, 
failure, loss, ESRD) classification1) or requirement of dialysis. 
 
AKIi was defined as a decrease in postoperative estimated creatinine clearance (Cockroft-Gault formula61) < 50 mL/min within the first 7 days after surgery; all 
patients had preoperative estimated creatinine clearance > 80 mL/min. Kheterpal et al.26 studied only a subgroup of patients to determine the association of ACEi 
or ARB use with AKI. 
 
AKIp was defined as an increase in serum creatinine concentration > 2.0 mg/dl within 72 hours of surgery. 
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Table 4: Studies: Preoperative ACEi or ARB use associated with less AKI 
 
Author Study Design, Setting and Patient Groups Key Results Conclusions Study 
Limitations 
Benedetto 
et al.
24 
 
 
Retrospective cohort study 
536 patients who underwent cardiac surgery 
between 2004 and 2008 
52.4% (281 out of 536) patients were on ACEi 
9.1% (49 out of 536) patients developed AKI (not 
requiring dialysis) and 4.3% (23 out of 536) 
patients developed AKI-D 
ACEi users vs. non-
users (referent): 
 
AKIg:  
Adjusted OR = 0.48;   
95% CI: 0.23 to 0.77; 
p = 0.04 
 
Preoperative 
ACEi use may 
decrease the risk 
of AKI after 
cardiac surgery 
Single centre 
study 
Only studied 
cardiac surgery 
Risk of  
overfitting in 
statistical model 
Barodka et 
al.
23  
 
 
Retrospective cohort study 
346 patients who underwent cardiac surgery 
between 2003 and 2007 
35% (122 out of 346) patients were on ACEi or 
ARB 
5.5% (19 out of 346) patients developed AKI and 
0.9% (3 out of 346) patients developed AKI-D 
ACEi or ARB users 
vs. non-users 
(referent): 
AKIh:  
Adjusted OR = 0.19;  
95% CI: 0.04 to 0.84;  
p = 0.029 
Preoperative 
ACEi or ARB 
may decrease 
the risk of AKI 
after cardiac 
surgery 
Single centre 
study 
Only studied 
cardiac surgery 
Risk of  
overfitting in 
statistical model 
 
OR: Odds ratio; CI: Confidence interval; AKI: Acute kidney injury; ACEi: Angiotensin converting enzyme inhibitor; ARB: Angiotensin receptor blocker; GFR: 
Glomerular filtration rate; AKI-D: AKI treated with dialysis 
AKIg was defined as a 50% or more decrease in GFR relative to preoperative baseline GFR value but not requiring dialysis and the modified diet and renal 
disease (MDRD) equation was used to estimate GFR.62 Benedetto et al.24 did not find significant association between preoperative ACEi use and 30-day all-
cause mortality. 
  
AKIh was defined with one of the following criteria: (1) increase in serum creatinine concentration above 2.0 mg/dL; (2) doubling of preoperative (baseline) 
serum creatinine concentration; (3) a requirement of postoperative dialysis. Barodka et al.23 did not find significant association between preoperative ACEi or 
ARB use and 30-day all-cause mortality. 
17 
 
 
Table 5: Postoperative AKI studies: Baseline differences in ACEi or ARB users and non-users 
 
Author No. of patients Baseline characteristics significantly higher in ACEi or ARB users 
compared to non-users (p-value < 0.05) 
Kheterpal et al.26 ACEi users: 9,143;  
non-users: 36,148 
Coronary artery disease, cerebrovascular disease, congestive heart failure, 
chronic obstructive pulmonary disease, diabetes mellitus, arrhythmia, 
hypertension, previous myocardial infarction, peripheral vascular disease, 
pulmonary hypertension, preoperative chronic kidney disease (serum creatinine 
≥ 2 mg/dL), age, beta-blocker use, diuretic use, calcium channel blocker use 
Miceli et al.21 ACEi users: 4,730; 
non-users: 4,544 
Hypertension, diabetes mellitus, vascular disease, previous myocardial 
infarction, coronary artery disease, age 
Ouzounian et al.49 ACEi users: 3,262; 
non-users: 2,684 
Hypertension, diabetes mellitus, congestive heart failure, previous myocardial 
infarction, cerebrovascular disease, peripheral vascular disease, chronic kidney 
disease, beta-blocker use, statin use 
Arora et al.22 ACEi or ARB users: 706;  
non-users: 652 
Diabetes mellitus, hypertension, congestive heart failure, body mass index 
(> 25 kg/m2)  
Benedetto et al.24 ACEi users: 281;  
non-users: 255 
Hypertension, beta-blocker use  
Yoo et al.28 ACEi or ARB users: 296; 
non-users: 176 
Diabetes mellitus, hypertension, diuretic use 
Barodka et al.23 ACEi or ARB users: 122; 
non-users: 224 
Hypertension, male gender 
AKI: Acute kidney injury; ACEi: Angiotensin converting enzyme inhibitor; ARB: Angiotensin receptor blocker 
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CHAPTER 3 – STUDY RATIONALE AND RESEARCH 
QUESTIONS  
 
3.1 Limitations of existing studies 
There are several methodological limitations of the existing studies on preoperative 
ACEi or ARB use and postoperative AKI.12;21-24;26-28;49;50;59;60  
(1) Study centres: All of the existing studies were limited to only single or two 
centres.  
(2) Sample size: The results for Cittanova et al.12, Arora et al.22, Railton et al.60 
Benedetto et al.24, Barodka et al.23, Yoo et al.28, Kincaid et al.27, and 
Ouzounian et al.49 were limited by the small sample size (249, 1358, 883, 536, 
346, 472, 1209, and 1647 patients respectively). One of the concerns due to 
small sample size is overfitting in statistical models.63;64 Overfitting in a 
statistical model occurs when it has more variables in respect to the amount of 
available data (e.g. A regression model requires a minimum of 10 to 12 events 
for every included variable to produce a stable regression model).63;64   
(3) Type of surgery: With the exception of Kheterpal et al.26, all of the existing 
studies were limited to only cardiac or vascular surgery. This raises concerns 
about the generalizability of the study results for other type of major surgery. 
(4) Study design: All of the existing studies are observational in nature and could 
not establish the causal association between preoperative ACEi or ARB use 
and postoperative AKI.65 
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3.2 Choice of study design 
The best estimates for treatment effects come from randomized controlled trials 
(RCT).65 However, a limitation to conducting such a trial on the outcome of AKI-D is 
one of logistics and cost.  
For example, a sample size of over 156,500 patients is needed to conduct an RCT on 
the outcome of AKI-D. (Assumptions: i) incidence of AKI-D of 0.45% in a group of 
patients having any type of major surgery, ii) 1:1 allocation (ACEi or ARB users vs. 
non-users), iii) relative risk reduction of 20% with ACEi or ARB use, iv) no loss to 
follow-up, v) two tailed α = 0.05, and vi) 1 – β = 0.8). It would not be possible to 
conduct such a large RCT.  
On the other hand, well designed cohort studies can provide useful information on 
estimates of treatment effects, and can guide the conduct and interpretation of future 
RCT.65 For this reason, we conducted a population based retrospective cohort study in 
Ontario, Canada to determine whether preoperative ACEi or ARB use compared to 
non-use is associated with an increased risk of AKI-D following a non-urgent major 
surgical procedure.  
3.3 Research Questions  
3.3.1 Primary research question 
In elderly patients undergoing non-urgent major surgery:  
Is preoperative ACEi or ARB use (vs. non-use) associated with a higher risk of 
postoperative AKI-D? 
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Hypothesis: Preoperative ACEi or ARB use increases the risk of AKI-D compared to 
non-use. 
3.3.2 Secondary research question 
In elderly patients undergoing non-urgent major surgery: 
Is preoperative ACEi or ARB use (vs. non-use) associated with an increased risk of 
postoperative all-cause mortality? 
Hypothesis: Preoperative ACEi or ARB use increases the risk of all-cause mortality 
compared to non-use. 
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CHAPTER 4 – STUDY METHODS  
 
4.1 Study overview and setting 
We performed a retrospective cohort study of elderly patients in the province of 
Ontario, Canada who were admitted to a hospital for a non-urgent, elective surgical 
procedure. We performed this study in accordance with a prespecified study protocol 
approved by the institutional review board (IRB) of Sunnybrook Health Sciences 
Centre, Toronto (detailed data creation plan in Appendix A). We used several linked 
Ontario health administrative databases held at ICES (Institute for Clinical Evaluative 
Sciences). We followed guidelines as stated in STROBE (Strengthening the Reporting 
of Observational Studies in Epidemiology) to report the findings of our study (detailed 
in Appendix B).66  
4.2 Data Sources 
All the residents in Ontario (Canada) have universal coverage for health-care services 
under the Ontario Health Insurance Plan (OHIP).17 Moreover, the Ontario Drug 
Benefits (ODB) plan covers routinely prescribed outpatient medications for patients 
65 years of age or older.17 Patients’ related health information such as vital status, 
demographics, outpatient health-care access, hospitalization, procedures (such as 
therapeutic, diagnostic, surgical procedures etc.), and drug prescriptions are 
electronically collected in several health administrative databases.17 The Institute for 
Clinical Evaluative Sciences has anonymously linked these databases for the purposes 
of population based health research.17;67-75  
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We used the following databases in our study:  
(1) Ontario Drug Benefits (ODB) Database: We reviewed the ODB database from 
September 1994 to November 2010 to obtain information on different 
outpatient medications such as drug identification number (DIN), therapeutic 
class etc.17 There was a minimal error rate of 0.7% (95% CI: 0.5% to 0.9%) on 
prescriptions dispended within this database.72  
(2) Canadian Institute for Health Information (CIHI) – Discharge Abstract 
Database (DAD): The CIHI-DAD collects information on hospital admissions 
including demographic and procedural information such as therapeutic, 
diagnostic, and surgical procedures.17 The CIHI-DAD used the Canadian 
Modified International Classification of Disease ninth version (ICD-9 CA) 
before 2002 and ICD-10 CA (10th version) thereafter. We reviewed the CIHI-
DAD from January 1992 to November 2010 to obtain various patients’ related 
health information.  
(3) Ontario Health Insurance Plan (OHIP) Database: The OHIP database records 
information on billing claims for inpatient, outpatient, and laboratory 
services.17 We reviewed the OHIP database from January 1992 to February 
2011. 
(4) Registered Persons Database (RPDB): The RPDB provides information on 
demographics and vital statistics such as vital status, socioeconomic status, 
birth-date, sex, and postal code for the residents in Ontario.17 We reviewed the 
RPDB from January 1992 to February 2011. 
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Table 6: Time Frame Definitions 
 
 
Accrual start date January 1, 1995  
End date November 30, 2010 
Maximum follow-up date 90 days after index date (February 28, 2011) 
When did follow-up window 
terminate? 
Whichever came first: a) death; or b) 90 
days after index date 
Look-back window(s) from 
index date 
3 years for comorbid conditions 
120 days for ODB medications 
 
4.3 Patients  
We selected patients’ over the age of 66 years who were admitted to a hospital in 
Ontario (Canada) for an elective, non-urgent surgical procedure between 
January 1, 1995 and November 30, 2010. Patients age 65 years or older receive 
universal prescription coverage under ODB plan in Ontario. Patients who were in their 
first year of coverage (age 65 years) were excluded to avoid incomplete medication 
records. We studied the following five surgical categories which all carry an 
appreciable risk for the complication of AKI-D4;17;20: 1) Cardiac; 2) Thoracic; 3) 
Vascular; 4) Abdominal; and 5) Retro-peritoneal (bladder, ureter, kidney).   
We defined the ‘index date’ as the date of elective, non-urgent surgical procedure 
during a hospital admission. If there was a missing procedural date, we used the 
hospital admission date.  
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We excluded all the surgeries done during the course of a non-surgical hospital 
admission to avoid selecting emergent or urgent surgery. We also excluded one 
hospital from analysis where a single treatment of intra-operative dialysis was 
routinely performed upon patients undergoing cardiopulmonary bypass surgery. 
In a data cleaning step, we excluded hospital admissions associated with invalid or a 
missing provincial health card number (ICES key number), missing age or sex, or any 
records with errors in vital statistics (< 1.2% of records excluded for these reasons). 
We limited our analyses to patients with at least one ODB prescription in the 120 days 
prior to the index date to ensure patients were assessing the ODB plan before surgery 
and were in Ontario. In order to assess of the event of new postoperative AKI-D, we 
excluded patients with any evidence of dialysis or kidney transplantation in the 3 
years prior to surgery.  
To avoid the need to account for less frequently prescribed anti-hypertensive 
medications in the analysis, we only considered those patients who could have 
evidence of a prescription for the following frequently prescribed anti-hypertensive 
medications in the 120 days prior to surgery: ACEi, ARB, beta-adrenergic blocker, 
calcium channel blocker, non-potassium sparing diuretic (loop diuretic and thiazide 
diuretic), and excluded remaining anti-hypertensive medications. For patients with 
multiple eligible surgical procedures during the study period, we selected one surgical 
procedure at random and excluded the remaining procedures to avoid within patient 
clustering in the analysis.   
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4.4 Preoperative ACEi or ARB use 
Within our study, our exposure group contained ACEi or ARB users, if there was 
evidence of at least one ODB prescription for an ACEi or ARB in the 120 days prior 
to the index date. Non-users (control group) had no evidence of an ODB prescription 
for an ACEi or ARB in the 120 days prior to the index date. We considered a time 
frame of 120 days because the ODB plan requires that each prescription be renewed at 
least every 100 days and we added 20 extra days to accommodate missed doses.76   
4.5 Baseline Characteristics 
We evaluated demographic characteristics and comorbidities for selected patients 
using validated database codes whenever possible (provided in Appendix C).17;77-85 
We also evaluated concomitant medications use in the 120 days prior to the index 
date. 
4.6 Potential Confounders 
We considered factors associated with ACEi or ARB use and those associated with 
postoperative AKI to determine potential confounders.4;11-13;17;20-28;30;49;50;59;60;86 
We adjusted for the following potential confounders in the logistic regression 
analysis: age (in years), sex (male/female; referent = female), chronic obstructive 
pulmonary disease (yes/no; referent = no), cerebrovascular disease (yes/no; referent = 
no), peripheral vascular disease (yes/no; referent = no), coronary artery disease 
(yes/no; referent = no), congestive heart failure (yes/no; referent = no), chronic kidney 
disease (yes/no; referent = no), chronic liver disease (yes/no; referent = no), 
antidiabetic agent (yes/no; referent = no), beta-adrenergic blocker (yes/no; referent = 
no), calcium channel blocker (yes/no; referent = no), non-potassium sparing diuretic 
26 
 
 
(yes/no; referent = no), statin (yes/no; referent = no), type of surgery (cardiac, 
thoracic, vascular, abdominal, retro-peritoneal; referent = abdominal), era of surgery 
(1995 to 1998, 1999 to 2001, 2002 to 2004, 2005 to 2007, 2008 to 2010; referent = 
1995 to 1998) 
4.7 Primary and secondary outcomes 
The primary outcome was AKI-D within 14 days of the index date. We assessed the 
primary outcome of AKI-D using OHIP database codes for acute dialysis (provided in 
Appendix D).17;87 The secondary outcome was all-cause mortality within 90 days of 
the index date.   
4.8 Primary Analysis 
Statistical analysis was performed using SAS 9.2 (SAS Institute, Cary, NC, USA). We 
evaluated differences in baseline characteristics between ACEi or ARB users and non-
users using standardized differences and considered > 10% as a meaningful difference 
between the two groups.86 For our primary and secondary outcomes, we determined 
the total number of events for ACEi or ARB users and non-users followed by 
unadjusted and adjusted logistic regression analysis with non-users as the referent 
group. We determined the unadjusted odds ratio (OR), the adjusted OR, and their 95% 
confidence intervals (CI). We adjusted for all the prespecified potential confounders 
in the logistic regression analysis to determine the adjusted OR. Given the low 
observed incidence for our study outcomes, we interpreted odds ratios as relative 
risks.88   
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4.9 Additional Analyses 
We conducted several additional analyses to explore the relationship between 
preoperative ACEi or ARB use and outcomes.  
(1) Propensity score matching: Cohort studies are prone to selection bias that 
might predispose a patient to receive or not receive ACEi or ARB prior to 
surgery.86;89-91 Because of this form of bias, cohort studies may be limited in 
their ability to make comparisons between ACEi or ARB users and non-
users.86;89-91 A propensity score matched analysis is a statistical approach to 
reduce this form of bias.89-91 In our context, we analyzed numerous risk factors 
that were associated with why a patient was or was not prescribed preoperative 
ACEi or ARB and assigned a propensity score – this score indicated the 
likelihood of ACEi or ARB use if the risk factor was present.86;89-91 When 
multiple risk factors were present in a single patient, we amalgamated the 
propensity scores for those risk factors and assigned an overall propensity 
score for that patient from 0 to 1 reflecting the likelihood of receiving ACEi or 
ARB.89 We then matched patients receiving preoperative ACEi or ARB on 
one-to-one basis with patients not receiving ACEi or ARB who had an 
identical overall propensity score.89 We excluded patients not successfully 
matched through this process.89  
In our study we performed an individual one-to-one match based on age (± 5 
years), sex (men/women) and the presence of chronic kidney disease (yes/no). 
We then derived a propensity score for every patient from all the potential 
confounders prespecified in our logistic regression analysis and matched each 
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ACEi or ARB user to a non-user using a caliper of ± 0.2 standard deviation of 
all the propensity scores.89 Through this process we obtained a group of 
matched cohort for ACEi or ARB users and non-users.89 Each non-user could 
only be selected once to derive the propensity score. For the primary and 
secondary outcomes, we determined the total number of events for propensity 
matched ACEi or ARB users and non-users followed by relative risk (95% 
CI). We also calculated absolute risk reduction (95% CI) for primary and 
secondary outcomes.88 In a case where preoperative ACEi or ARB use was 
beneficial, we calculated the number needed to treat (1 / absolute risk 
reduction), which indicates how many patients need to receive preoperative 
ACEi or ARB to prevent one patient from developing an event such as receipt 
of AKI-D who otherwise would have developed the event (a lower number 
indicating a more beneficial effect of ACEi or ARB use).88 
(2) Effect modification by preoperative chronic kidney disease, era of surgery, 
and type of surgery: We performed subgroup analyses (tests of effect 
modification) for the outcome of AKI-D and all-cause mortality for the 
following three characteristics: presence of preoperative chronic kidney 
disease (yes/no), era of surgery (1995 to 1998, 1999 to 2001, 2002 to 2004, 
2005 to 2007, 2008 to 2010), and type of surgery (cardiac, thoracic, vascular, 
abdominal, retro-peritoneal). We fit a logistic regression model to perform 
subgroup analyses where we adjusted for all the prespecified potential 
confounders except the subgroup factor being tested. We determined the total 
number of events and event rate per 10,000 persons followed by the 
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unadjusted and adjusted relative risk (95% CI). We considered a p-value < 
0.05 for the test of effect modification to be significant.   
(3) Time to event analysis: We repeated our analysis using a Cox-proportional 
hazards model for the outcome of AKI-D, censored for death or end of the 14th 
day after index date. We adjusted for all prespecified potential confounders 
and determined the adjusted hazard ratio (95% CI) for ACEi or ARB users 
with non-users as the referent group.   
 
30 
 
 
CHAPTER 5 – STUDY RESULTS  
 
5.1 Baseline characteristics: ACEi or ARB users and non-users          
We identified 237,208 patients from 118 hospitals in Ontario (Canada) after applying 
our selection criteria (Figure 3). There were 101,494 (42.8%) ACEi or ARB users and 
135,714 (57.2%) non-users. The baseline characteristics for ACEi or ARB users and 
non-users are presented in Table 7. In comparison to non-users, ACEi or ARB users 
were more likely to be male, were on a higher number of medications such as anti-
diabetic agent, other anti-hypertensive medications (beta-blocker, calcium channel 
blocker, and non-potassium sparing diuretic) and statin, had higher rates of 
cerebrovascular disease, peripheral vascular disease, coronary artery disease including 
angina, congestive heart failure, and chronic kidney disease. ACEi or ARB users were 
more likely to undergo cardiac and vascular surgeries compared to other types of 
eligible surgeries. Patients having their surgery in more recent years (2002 to 2010) 
were more likely to have received preoperative ACEi or ARB compared to past years 
(1995 to 2001). 
5.2 Primary analysis: AKI-D and all-cause mortality 
The incidence of postoperative AKI-D (within 1 to 14 days after surgery) was 0.34% 
(810 out of 237,208 patients) and postoperative 90-day all-cause mortality was 4.67% 
(11,089 out of 237,208 patients). After adjustment for prespecified potential 
confounders, ACEi or ARB use prior to surgery was associated with a lower relative 
risk of AKI-D (adjusted relative risk (RR): 0.83; 95% CI: 0.71 to 0.98) and a lower 
relative risk of 90-day all-cause mortality (adjusted RR: 0.91; 95% CI: 0.87 to 0.95) 
(Table 8). 
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5.3 Additional Analyses 
5.3.1 Propensity score matched analysis: AKI-D and all-cause mortality 
Out of 101,494 ACEi or ARB users selected for the primary analysis, 67,822 ACEi or 
ARB users were matched to 67,822 non-users using predefined characteristics 
including the propensity score (Table 7). Similar to the primary analysis, preoperative 
ACEi or ARB use was associated with a lower relative risk of AKI-D (RR: 0.77; 95% 
CI: 0.65 to 0.92) and a lower relative risk of 90-day all-cause mortality (RR: 0.93; 
95% CI: 0.88 to 0.97) (Table 9). For the outcome of AKI-D, the absolute risk 
reduction (ARR) for ACEi or ARB users compared to non-users was 0.09% and 
number needed to treat (NNT) was 1,077. It indicates that 1,077 patients need to be 
treated with ACEi or ARB prior to surgery to prevent one case of postoperative AKI-
D. Similarly, for the outcome of 90-day all-cause mortality, the ARR for ACEi or 
ARB users compared to non-users was 0.35%, and the NNT was 289.  
5.3.2 Subgroup analysis for AKI-D and all-cause mortality 
We summarized the results for subgroup analysis for AKI-D and all-cause mortality in 
Table 10 and Table 11. We did not find type of surgery or era of surgery modified the 
association between preoperative ACEi or ARB use and AKI-D. For patients with 
chronic kidney disease, we observed a lower incidence of AKI-D (246.8 per 10,000 
persons) in preoperative ACEi or ARB users compared to non-users (354.1 per 10,000 
persons). Preoperative ACEi or ARB use in patients with chronic kidney disease was 
associated with a lower relative risk of AKI-D (adjusted RR: 0.62; 95% CI: 0.50 to 
0.78), while there was no such association in patients without chronic kidney disease 
(adjusted RR: 1.00; 95% CI: 0.81 to 1.24), with a significant test of interaction by the 
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presence of chronic kidney disease (p-value < 0.0001). We did not find significant 
effect modification by chronic kidney disease, type of surgery, or era of surgery on the 
outcome of all-cause mortality. 
5.3.3 Time to event analysis for AKI-D  
We observed similar result in the time to event analysis for AKI-D. The adjusted 
hazard ratio for preoperative ACEi or ARB use compared to non-use was 0.83 (95% 
CI: 0.71 to 0.97).  
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Figure 3: Flow diagram: Patient selection 
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Hospital admissions for cardiac surgery, vascular surgery, thoracic 
surgery, abdominal surgery and retro-peritoneal surgery during 
1995 to 2010 in 118 hospitals in Ontario, Canada 
Total No. of hospital admissions: 1,762,271 (100%) 
 
Excluded 1,486,482 (84.35%) hospital admissions with: 
• Surgery performed during non-surgical hospital 
admissions: 915,524 (51.95%) 
• Coding error for acute dialysis (AKI-D) at one of the 
hospitals: 7,145 (0.41%) 
• Death prior to index date: 172 (0.01%) 
• Missing or invalid identification or demographic 
information (age and sex): 19,934 (1.13%)  
• Patients < 66 years: 487,049 (27.64%) 
• Non-Ontario residents: 80 (~0.00%) 
• Past history of dialysis or renal transplantation in 3 years 
prior to surgery: 7,180 (0.41%) 
• No evidence of Ontario Drug Benefit plan use in the past 
120 days prior to surgery: 14,315 (0.81%) 
• Patients on less prevalent anti-hypertensive medications: 
35,083 (1.99%) 
 
Hospital admissions 
(for elective surgery) 
meeting inclusion 
criteria: 275,789 
Randomly selected one surgical 
procedure for patients with multiple 
eligible surgical procedures and 
excluded 38,581 (2.19%) hospital 
admissions 
Hospital admission for 
patients with one 
elective surgical 
procedure: 237,208 
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Table 7: Baseline characteristics: ACEi or ARB users and non-users 
 Entire Cohort  Propensity Matched Cohort 
 ACEi or ARB 
users 
Non-users 
(control) 
 ACEi or ARB 
users 
Non-users 
(control) 
 N=101,494 N=135,714  N=67,822 N=67,822 
Demographics       
Age at index date (years) 74 (70 to 78) 73 (69 to 78)  74 (70 to 78) 74 (70 to 78) 
Age groups (years)      
66 to 70 30,557 (30.1%) 43,652 (32.2%)  20,098 (29.6%) 20,165 (29.7%) 
71 to 75 30,966 (30.5%) 40,782 (30.0%)  20,482 (30.2%) 20,391 (30.1%) 
76 to 80 23,898 (23.5%) 29,529 (21.8%)  15,982 (23.6%) 15,779 (23.3%) 
81 to 85 11,812 (11.6%) 15,361 (11.3%)  8,101 (11.9%) 8,205 (12.1%) 
86 to 90 3,651 (3.6%) 5,294 (3.9%)  2,682 (4.0%) 2,761 (4.1%) 
91+ 610 (0.6%) 1,096 (0.8%)  477 (0.7%) 521 (0.8%) 
      
Women 41,034 (40.4%) 60,522 (44.6%)  29,425 (43.4%) 29,425 (43.4%) 
      
Comorbidities      
Chronic obstructive pulmonary disease 5,806 (5.7%) 7,121 (5.2%)  3,789 (5.6%) 3,527 (5.2%) 
Cerebrovascular disease 18,016 (17.8%)* 17,551 (12.9%)*  10,970 (16.2%) 11,097 (16.4%) 
Peripheral vascular disease 6,490 (6.4%)* 5,571 (4.1%)*  3,675 (5.4%) 3,599 (5.3%) 
Coronary artery disease 67,921 (66.9%)* 61,137 (45.0%)*  40,114 (59.1%) 40,346 (59.5%) 
Congestive heart failure 22,108 (21.8%)* 12,413 (9.1%)*  10,740 (15.8%) 10,317 (15.2%) 
Chronic kidney disease 7,538 (7.4%)* 5,027 (3.7%)*  3,852 (5.7%) 3,852 (5.7%) 
Chronic liver disease 295 (0.3%) 478 (0.4%)  200 (0.3%) 194 (0.3%) 
      
Medications       
Oral hypoglycemic 21,267 (21.0%)* 10,381 (7.6%)*  8,766 (12.9%) 8,625 (12.7%) 
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Insulin 6,089 (6.0%)* 2,381 (1.8%)*  2,348 (3.5%) 1,937 (2.9%) 
Anti-diabetic agent 25,041 (24.7%)* 12,215 (9.0%)*  10,364 (15.3%) 10,076 (14.9%) 
Beta-adrenergic blocker 44,835 (44.2%)* 34,096 (25.1%)*  24,550 (36.2%) 24,702 (36.4%) 
Calcium channel blocker 36,659 (36.1%)* 32,859 (24.2%)*  21,630 (31.9%) 22,131 (32.6%) 
Non-potassium sparing diuretic 40,345 (39.8%)* 22,042 (16.2%)*  19,830 (29.2%) 19,595 (28.9%) 
Statin 53,915 (53.1%)* 31,691 (23.4%)*  27,348 (40.3%) 26,913 (39.7%) 
      
Surgical Characteristics      
Type of Surgery      
Cardiac surgery 40,694 (40.1%)* 29,475 (21.7%)*  22,222 (32.8%) 22,380 (33.0%) 
Thoracic surgery 5,771 (5.7%) 10,177 (7.5%)  4,561 (6.7%) 4,176 (6.2%) 
Vascular surgery 18,459 (18.2%)* 18,969 (14.0%)*  11,509 (17.0%) 11,904 (17.5%) 
Abdominal surgery 30,471 (30.0%)* 64,911 (47.8%)*  24,592 (36.2%) 24,630 (36.3%) 
Retro-peritoneal surgery 6,099 (6.0%)* 12,182 (9.0%)*  4,938 (7.3%) 4,732 (7.0%) 
      
Era of surgery      
1995 to 1998 14,718 (14.5%)* 45,173 (33.3%)*  13,278 (19.6%) 13,647 (20.1%) 
1999 to 2001 16,900 (16.6%)* 30,122 (22.2%)*  13,457 (19.8%) 13,963 (20.6%) 
2002 to 2004 20,960 (20.7%)* 21,992 (16.2%)*  13,404 (19.8%) 13,194 (19.5%) 
2005 to 2007 23,711 (23.4%)* 19,520 (14.4%)*  13,625 (20.1%) 13,300 (19.6%) 
2008 to 2010 25,205 (24.8%)* 18,907 (13.9%)*  14,058 (20.7%) 13,718 (20.2%) 
ACEi: Angiotensin converting enzyme inhibitor; ARB: Angiotensin receptor blocker 
 
Data are presented as number (percentage (rounding off to one decimal place)) with the exception of age at index date. Age at index date is presented as median 
(interquartile range). Index date is a surgical procedure date or a hospital admission date (if the surgical procedure date is not available). 
 
*Represents a standardized difference of > 10% between ACEi or ARB users and non-users. We considered a standardized difference of > 10% between ACEi or 
ARB users and non-users as a meaningful difference.86 Standardized differences are not much sensitive to sample size compared to traditional hypothesis tests.86 
It is calculated by examining the difference between ACEi or ARB users and non-users divided by the pooled standard deviation of the two groups.86 
A total of 3% (3,091 out of 101,494) patients were on both ACEi and ARB medication.   
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Table 8: Association between preoperative ACEi or ARB use and outcomes 
Outcomes No. of patients with event (percent) Relative Risk 
(95% Confidence Interval) 
ACEi or ARB users  Non-users  Unadjusted Adjusted* 
(N=101,494) (N=135,714) 
AKI-D  
(1 to 14 days after surgery) 
438 (0.43%) 372 (0.27%) 1.58 (1.37, 1.81) 0.83 (0.71, 0.98) 
Death  
(1 to 90 days after surgery) 
4,654 (4.59%) 6,435 (4.74%) 0.97 (0.93, 1.00) 0.91 (0.87, 0.95) 
ACEi: Angiotensin converting enzyme inhibitor; ARB: Angiotensin receptor blocker; AKI-D: Acute kidney injury treated with dialysis 
 
Relative risk was calculated for preoperative ACEi or ARB use compared to non-use 
 
*Adjusted for age, sex, chronic obstructive pulmonary disease, cerebrovascular disease, peripheral vascular disease, coronary artery disease, congestive heart 
failure, chronic kidney disease, chronic liver disease, anti-diabetic agent, beta-adrenergic blocker, calcium channel blocker, non-potassium sparing diuretic, 
statin, type of surgery (cardiac, thoracic, vascular, abdominal, retro-peritoneal), era of surgery (1995-1998, 1999-2001, 2002-2004, 2005-2007, 2008-2010)
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Table 9: Propensity score matched analysis: Preoperative ACEi or ARB use and outcomes 
Outcomes No. of patients with event 
(percent) 
 
Relative Risk 
(95% CI) 
 
Absolute Risk 
Reduction  
(95% CI) 
Number 
Needed to 
Treat
+  
ACEi or ARB 
users  
Non-users  
(N=67,822) (N=67,822) 
AKI-D  
(1 to 14 days after surgery) 
215 (0.32%) 278 (0.41%) 0.77 (0.65, 0.92) 0.09% (0.03%, 0.16%) 1,077 
Death  
(1 to 90 days after surgery) 
3,060 (4.51%) 3,295 (4.86%) 0.93 (0.88, 0.97) 0.35% (0.12%, 0.57%) 289 
ACEi: Angiotensin converting enzyme inhibitor; ARB: Angiotensin receptor blocker; AKI-D: Acute kidney injury treated with dialysis; CI: Confidence interval 
 
Relative risk was calculated for preoperative ACEi or ARB use compared to non-use 
  
+The number needed to treat is the reciprocal of the absolute risk reduction (1 / absolute risk reduction) and indicates the total number of patients who need to be 
treated with an ACEi or ARB prior to surgery to prevent one case of AKI-D or death, respectively.88  
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Table 10: Subgroup analysis for AKI-D 
 
 No. of events Event rate 
per 10,000 persons 
Relative Risk 
(95% Confidence Interval) 
P-value  
(Test for 
interaction)  ACEi or 
ARB users 
Non-users ACEi or 
ARB users 
Non-
users 
Unadjusted Adjusted+ 
CKD        
Yes 186 / 7,538 178 / 5,027 246.75 354.09 0.69 (0.56, 0.85) 0.62 (0.50, 0.78) }< 0.0001 No 252 / 93,956 194 / 130,687 26.82 14.84 1.81 (1.50, 2.18) 1.00 (0.81, 1.24) 
        
Era of surgery        
1995 to 1998 77 / 14,718 113 / 45,173 52.32 25.01 2.10 (1.57, 2.80) 1.13 (0.81, 1.56) 
}NS 1999 to 2001 57 / 16,900 68 / 30,122 33.73 22.57 1.50 (1.05, 2.13) 0.78 (0.53, 1.15) 2002 to 2004 93 / 20,960 66 / 21,992 44.37 30.01 1.48 (1.08, 2.03) 0.88 (0.62, 1.25) 
2005 to 2007 92 / 23,711 63 / 19,520 38.80 32.27 1.20 (0.87, 1.66) 0.64 (0.45, 0.92) 
2008 to 2010 119 / 25,205 62 / 18,907 47.21 32.79 1.44 (1.06, 1.96) 0.84 (0.60, 1.17) 
        
Type of surgery        
Cardiac 232 / 40,694 147 / 29,475 57.01 49.87 1.14 (0.93, 1.41) 0.74 (0.59, 0.93) 
}NS Thoracic 14 / 5,771 12 / 10,177 24.26 11.79 2.06 (0.95, 4.46) 1.84 (0.77, 4.40) Vascular 117 / 18,459 92 / 18,969 63.38 48.50 1.31 (0.99, 1.72) 1.09 (0.80, 1.48) 
Abdominal 71 / 30,471 109 / 64,911 23.30 16.79 1.39 (1.03, 1.87) 0.72 (0.52, 1.01) 
Retro-peritoneal 4 / 6,099 12 / 12,182 6.56 9.85 0.67 (0.22, 2.07) 0.94 (0.28, 3.22) 
AKI-D: Acute kidney injury treated with dialysis; ACEi: Angiotensin converting enzyme inhibitor; ARB: Angiotensin receptor blocker; CKD: Chronic kidney 
disease; NS: not significant;  
 
Relative risk was calculated for preoperative ACEi or ARB use compared to non-use 
 
+ For adjusted analyses, we included all the prespecified potential confounders except the subgroup factor being tested 
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Table 11: Subgroup analysis for all-cause mortality 
 
 No. of events Event rate 
per 10,000 persons 
Relative Risk 
(95% Confidence Interval) 
P-value  
(Test for 
interact-
ion) 
 ACEi or ARB 
users 
Non-users ACEi or 
ARB users 
Non-
users 
Unadjusted Adjusted+ 
CKD        
Yes 606 / 7,538 467 / 5,027 803.93 928.98 0.85 (0.75, 0.97) 0.86 (0.75, 0.98) }NS No 4,048 / 93,956 5,968 / 130,687 430.84 456.66 0.94 (0.90, 0.98) 0.91 (0.87, 0.96) 
        
Era of surgery        
1995 to 1998 846 / 14,718 2,077 / 45,173 574.81 459.79 1.27 (1.17, 1.37) 1.05 (0.95, 1.15) 
}NS 1999 to 2001 790 / 16,900 1,418 / 30,122 467.46 470.75 0.99 (0.91, 1.09) 0.96 (0.87, 1.06) 2002 to 2004 922 / 20,960 1,089 / 21,992 439.89 495.18 0.88 (0.81, 0.97) 0.87 (0.79, 0.96) 
2005 to 2007 1,005 / 23,711 967 / 19,520 423.85 495.39 0.85 (0.78, 0.93) 0.81 (0.74, 0.90) 
2008 to 2010 1,091 / 25,205 884 / 18,907 432.85 467.55 0.92 (0.84, 1.01) 0.90 (0.82, 0.99) 
        
Type of surgery        
Cardiac 1,460 / 40,694 1,184 / 29,475 358.78 401.69 0.89 (0.82, 0.96) 0.82 (0.75, 0.89) 
}NS Thoracic 432 / 5,771 830 / 10,177 748.57 815.56 0.91 (0.81, 1.03) 1.00 (0.87, 1.15) Vascular 936 / 18,459 916 / 18,969 507.07 482.89 1.05 (0.96, 1.16) 1.02 (0.91, 1.13) 
Abdominal 1,625 / 30,471 3,112 / 64,911 533.29 479.43 1.12 (1.05, 1.19) 0.92 (0.86, 0.99) 
Retro-peritoneal 201 / 6,099 393 / 12,182 329.56 322.61 1.02 (0.86, 1.23) 0.92 (0.76, 1.13) 
ACEi: Angiotensin converting enzyme inhibitor; ARB: Angiotensin receptor blocker; CKD: Chronic kidney disease; NS: not significant;  
 
Relative risk was calculated for preoperative ACEi or ARB use compared to non-use 
 
+ For adjusted analyses, we included all the prespecified potential confounders except the subgroup factor being tested
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CHAPTER 6 – GENERAL DISCUSSION  
 
6.1 Summary of study results 
The benefits of chronic ACEi or ARB use in reducing cardiovascular morbidity and 
mortality have been established in several international randomized controlled 
trials.32-38 However, optimal ACEi or ARB use in the perioperative period is still a 
matter of debate and practice patterns vary on whether these medications should be 
used or temporarily held prior to surgery.21;22;40-42;51-53  
We conducted a large population based retrospective cohort study to determine 
whether ACEi or ARB use prior to elective surgery is associated with a higher risk of 
AKI-D. Contrary to our hypothesis, ACEi or ARB use prior to surgery was associated 
with 17% lower relative risk of AKI-D and 9% lower relative risk of 90-day all-cause 
mortality after adjusting for relevant baseline characteristics. We observed similar 
results with propensity score matched analyses.  However, we observed a significant 
effect modification by chronic kidney disease on AKI-D and the benefit of 
preoperative ACEi or ARB use in reducing the risk of AKI-D was only observed in 
patients with chronic kidney disease. 
6.2 Interpreting study results 
There is a supporting biological rationale which explains why ACEi or ARB use may 
improve outcomes in the perioperative setting. Both ACEi and ARB reduce the 
activity of angiotensin II which is thought to result in kidney protection.25;30;45-48 There 
are at least four potential mechanisms by which angiotensin II may increase the risk of 
postoperative AKI and mortality: i) Angiotensin II is a potent vasoconstrictor and acts 
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directly on the renal efferent arteriole, severely altering renal hemodynamics, ii) it 
increases super oxide anion production and can lead to oxidative stress and impaired 
endothelial function, iii) it can accelerate the inflammatory response by promoting 
release of inflammatory mediators, adhesion molecules, and proinflammatory 
transcription factors, and iv) it accelerates acute ischemic events by increasing the 
release of plasminogen activator inhibitor-1.25;30;45-48 By reducing the activity of 
angiotensin II, ACEi or ARB may prevent the aforementioned events from increasing 
risk of kidney damage and death.25;30;45-48  
Our results are consistent with two previous small studies (studies summarized in 
Table 3). Benedetto et al.24 studied 536 patients who underwent cardiac surgery and 
noted that preoperative ACEi use compared to non-use was associated with a lower 
risk of postoperative AKI (adjusted OR: 0.48;  95% CI: 0.23 to 0.77). The authors 
speculated the pathophysiologic benefit of ACEi use stemmed from preservation of 
renal blood flow during surgery.24 Following 346 patients who underwent cardiac 
surgery, Barodka et al.23 observed that preoperative ACEi or ARB use compared to 
non-use was associated with a substantially lower risk of AKI (adjusted OR: 0.19; 
95% CI: 0.04 to 0.84). Contrary to our results, neither Benedetto et al.24 or Barodka et 
al.23 found a statistically significant association between preoperative ACEi or ARB 
use and all-cause mortality.   
Miceli et al.21 performed a propensity score matched analysis in 9,274 patients who 
underwent cardiac surgery and observed that preoperative ACEi use compared to non-
use was associated with a 1.36 fold higher risk of postoperative AKI (adjusted OR: 
1.36; 95% CI: 1.10 to 1.67) and a two-fold higher risk of postoperative mortality 
42 
 
 
(adjusted OR: 2.00; 95% CI: 1.17 to 3.42). Miceli et al.21 suggested that postoperative 
AKI occurred as a result of decreased renal perfusion, mainly due to decreased arterial 
pressure along with increased intraoperative use of vasoconstrictors.  
An additional four epidemiological studies conducted by Ouzounian et al.49, Rady et 
al.50, Yoo et al.28, and Barodka et al.59 (studies summarized in Table 4), demonstrated 
no significant association between preoperative ACEi or ARB use and postoperative 
AKI. However, all the four studies observed a non-significant trend towards benefit 
with preoperative ACEi or ARB use (adjusted OR < 1.00; p-value: not significant) 
and these could have been due to insufficient statistical power to detect a meaningful 
clinical benefit.28;49;50;59 
The major considerations in comparing our study results with all previous studies are 
the heterogeneous AKI definitions and type of surgery studied.12;21-24;26-28;49;50;59;60 We 
studied the outcome of AKI-D, the renal outcome most important to patients and their 
health-care providers.92 It differs from an outcome of AKI defined by acute changes in 
serum creatinine.1;5 The latter is a surrogate outcome, and could be misleading 
particularly in the ACEi or ARB use setting (i.e. ACEi or ARB use versus placebo 
may increase serum creatinine concentration but prevents the most clinically 
important renal outcome of end-stage renal disease requiring on-going maintenance 
dialysis).22;25;29;30;44 Out of all previous studies on this issue12;21-24;26-28;49;50;59;60, only 
Railton et al.60 studied the outcome of AKI-D and observed a higher risk for AKI-D 
with preoperative ACEi or ARB use (summarized in Table 2). However, the study 
was limited by a small group of patients (883 patients) who underwent abdominal 
aortic aneurysm (AAA) repair and a small number of AKI-D events (24 events).60  
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Contrary to our study and Railton et al.60, the remaining studies defined AKI using 
different criteria12;21-24;26-28;49;50;59, such as: i) a composite outcome on changes in 
serum creatinine and AKI-D, ii) changes in serum creatinine using RIFLE 
classification1, iii) changes in serum creatinine using arbitrary criteria, iv) changes in 
creatinine clearance or glomerular filtration rate (AKI definitions provided in 
footnotes of Table 2, 3, and 4). Different from our study and Kheterpal et al.26, all 
existing previous studies considered only cardiac or vascular surgery to examine the 
association with postoperative AKI.12;21-24;27;28;49;50;59;60 However, Kheterpal et al.26, 
after applying their selection criteria of overnight hospital admission, no urological 
procedure, and normal preoperative renal function, only studied a subgroup of patients 
(3,256 patients) out of a large cohort (45,291 patients) who underwent non-cardiac 
surgery. Kheterpal et al.26 observed no significant association between preoperative 
ACEi or ARB use and postoperative AKI and surmised this was potentially due to the 
limited small sample size. 
Although we observed a lower relative risk of AKI-D with preoperative ACEi or ARB 
use, the benefit was only seen in patients with chronic kidney disease, while we found 
no significant association in patients without chronic kidney disease. Chronic kidney 
disease is considered to be the most important risk factor for AKI.13;20 However, 
majority of the previous studies did not account for chronic kidney disease in their 
analyses, so we do not know whether this explains differences in study results.12;21-
24;26-28;49;50;59;60 
6.3 Study Strengths  
Our study has a number of strengths:  
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(1) The large sample size (237,208 patients) from 118 hospitals in Ontario 
increased the generalizability of the study results.  
(2) Statistical overfitting with poor regression modeling can occur when there are 
less than 10 to 12 events for every variable included in the regression 
analysis.63;64 Unlike other studies, the large number of events for the primary 
outcome in our study (AKI-D, 810 events) reduced concerns about statistical 
overfitting.23;24;63;64  
(3) To the best of our knowledge, this is the largest cohort study to examine the 
association between preoperative ACEi or ARB use and postoperative AKI. 
(4) AKI prevention is important for both cardiac and non-cardiac major surgeries. 
This is first study of its kind that considered both cardiac and non-cardiac 
major surgeries (including thoracic, vascular, abdominal and retro-peritoneal 
surgeries). 
(5) Given there were less than 1% yearly emigration from Ontario, the loss to 
follow up was minimal.93 
(6) The information in Ontario health administrative databases reflects routine 
clinical practice and therefore, less prone to screening biases that could arise in 
other types of studies.17;70;71;73  
(7) Our data sources provided accurate information on the dispensing of different 
outpatient medication prescriptions with a minimal error rate of 0.7% (95% 
CI: 0.5% to 0.9%).72 
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6.4 Study Limitations 
The study does have some limitations:  
(1) Confounding by indication, due to non random allocation of treatment, is well 
described in observational studies related to pharmacoepidemiology.89-91 
Because of this issue, the associations observed in this study may not be 
causal.89-91 In other words, it is possible the results observed in this study are 
attributable to residual confounding rather than a true ACEi or ARB 
effect.90;91;94;95 Patients with comorbidities such as chronic kidney disease, 
diabetes, hypertension, congestive heart failure, coronary artery disease, and 
peripheral vascular disease are more likely to receive an ACEi or ARB, and 
these comorbidities also increase the risk for AKI.4;11;13;20;21;25;26 To deal with 
confounding, we adjusted for potential confounders in logistic regression 
analysis.89-91;95 We also repeated our analysis using propensity score 
matching.89-91;95 It is reassuring that these different methods of analysis 
provided similar results. However, we were unable to adjust for certain 
variables that were not available in our data sources, i.e. race, body mass 
index, non-prescription medication use, in hospital medication use, and 
medication compliance.17  
(2) Accuracy of codes: One of the concerns using health administrative databases 
is the accuracy of codes for patient related health information, e.g. chronic 
kidney disease (CKD) is considered to be the most important risk factor for 
postoperative AKI and the validity of database codes for CKD is limited 
(sensitivity: 28.3%; specificity: 94.6%; positive predictive value: 51.9%; 
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negative predictive value: 86.5%; compared with the reference standard of 
estimated GFR < 60 mL/min/1.73m2).83 However, we used validated database 
codes whenever possible.17;77-85  
(3) A key information gap in our study was that we did not have complete 
information on perioperative ACEi or ARB use. We cannot determine whether 
patients took their ACEi or ARB around the time of surgery. We did not know: 
(a) whether it was held prior to surgery and if so which day prior to surgery it 
was held; (b) if it wasn’t held whether the full dose was used just prior to 
surgery, and (c) if ACEi or ARB was held prior to surgery, if and when it was 
restarted after surgery during the hospital stay. These are critical issues to 
guide the safe and optimal use of these medications in the perioperative 
period.40-42;51-53 
6.5 Future Directions 
Future research studies will better clarify the relationship between preoperative ACEi 
or ARB use and postoperative AKI.  
(1) Prospective cohort studies: Well conducted large multi-centre prospective 
cohort studies may provide better information on this association.65 In this 
regard we have been funded by the Canadian Institutes of Health Research to 
study the association between preoperative ACEi or ARB use and AKI in an 
international prospective cohort study, VISION (Vascular Events In 
Noncardiac Surgery Patients Cohort Evaluation Study; Principal investigator: 
Dr. PJ Devereaux, McMaster University). In this study AKI will be defined by 
a ≥ 100% increase in serum creatinine defined according to RIFLE 
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classification.1 VISION includes patients’ aged 45 years or more undergoing 
major noncardiac surgery requiring hospitalization. The data collection 
includes detailed information on demographic characteristics, comorbidities, 
preoperative and postoperative serum creatinine measurement, postoperative 
AKI-D, preoperative medications use and whether these medications are 
temporarily withheld prior to surgery or not. Further, chronic kidney disease is 
classified according to estimated glomerular filtration rate categories based on 
modified diet and renal disease (MDRD) equation.62 This will provide better 
information on a key comorbid condition as opposed to our current study 
where the presence of chronic kidney disease was determined with poorly 
validated database codes.83 Moreover, we will be able to explore the impact of 
holding vs. not holding ACEi or ARB prior to surgery. We expect to study a 
sample of over 30,000 patients recruited across multiple countries after 
applying our selection criteria.  
(2) Future randomized controlled trials: Large randomized controlled trials are 
required to establish the causal association between preoperative ACEi or 
ARB use and postoperative outcomes.22;24;65 If one were to consider a primary 
outcome of 90-day all-cause mortality, the sample size would be 15,100 
patients (Assumptions: i) incidence of 90-day all-cause mortality in 4.5% of 
patients undergoing major surgery, ii) 1:1 allocation for ACEi or ARB users 
and non-users, iii) relative risk difference: 20%, iv) no loss to follow-up, v) 
two tailed, α = 0.05, and vi) 1 – β = 0.8)). The sample size could be smaller if 
it proves reasonable to study the outcome of AKI defined according to changes 
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in serum creatinine.1;5 Given the signal of benefit was strongest in the 
subgroup of patients with chronic kidney disease, enrolling a large number 
patients with chronic kidney disease may be prudent. 
  
6.6 Study Implications  
AKI-D is a serious complication of major surgery. Our study results suggest that 
preoperative ACEi or ARB use in older people may protect against the complication 
of AKI-D and may also reduce the risk of postoperative mortality. However, we 
observed the benefits of preoperative ACEi or ARB use in reducing the risk of AKI-D 
only in chronic kidney disease patients. Moreover, we cannot rule out the possibility 
of residual confounding and we did not have key information regarding the nature of 
ACEi or ARB use in the perioperative period. Large randomized controlled trials are 
required to address this issue.  
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APPENDICES 
 
Appendix A: Data creation plan submitted to ICES 
 
Name and 
number of 
study 
Acute dialysis following non-urgent surgery: incidence, trends, risk 
factors, and outcomes: Preoperative ACEi or ARB use  
2009 0809 010 000 
PIA 
approved? 
Yes, 2009 0809 010 000  
(E-mail from Conrad Pow Feb 11th, 2009) 
Data 
creation 
plan 
(DCP) 
update 
history 
 
(AG: Amit 
Garg;  
AJ: Arsh 
Jain;  
MS: Mitesh 
Shah;  
SS: Salimah 
Shariff;  
JL: Jin Luo) 
Version 24: February 24, 2012 (MS; after a conference call with JL) 
Version 23: February 21, 2012 (MS; after an email from JL) 
Version 22: February 14, 2012 (MS, AG, and AJ) 
Version 21: February 06, 2012 (MS; after a conference call with JL) 
Version 20: January 25, 2012 (MS, AG, and AJ) 
Version 19: November 22, 2011 (MS, AG, and SS) 
Version 18: November 15, 2011 (MS; after discussion with AG) 
Version 17: November 04, 2011 (MS; after discussion with SS) 
Version 16: November 03, 2011 (MS; after discussion with SS) 
Version 15: October 18, 2011 (MS; after discussion with SS) 
Version 14: September 20, 2011 (MS, AG, and AJ) 
Version 13: September 11, 2011 (MS; after discussion with SS) 
Version 12: August 24, 2011 (MS; after discussion with AG) 
Version 11: July 21, 2011 (MS; after discussion with AG) 
Version 10: July 07, 2011 (MS; after discussion with AG and AJ) 
Version 9: July 06, 2011 (MS; after discussion with AG) 
Version 8: June 20, 2011 (MS; after discussion with AG) 
Version 7: June 09, 2011 (MS; after discussion with AG) 
Version 6: February 02, 2011 (MS; after discussion with AG) 
Version 5: December 20, 2010 (MS) 
Version 4: November 23, 2010 (MS; after discussion with AG) 
Version 3: September 28, 2010 (MS) 
Version 2: September 21, 2010 (MS; after discussion with AG) 
Version 1: August-September 2010 (MS; after discussion with AG) 
Short 
description 
of research 
questions 
Research project objective:  
To determine whether preoperative ACEi (angiotensin converting 
enzyme inhibitor) or ARB (angiotensin receptor blocker) use is 
associated with an increased risk of AKI-D following major non-
urgent surgery. 
 
Hypothesis:  
Preoperative ACEi or ARB use increases the risk of AKI-D 
compared to non-use. 
 
Design:   
Retrospective cohort study with the following population of interest: 
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Individuals age ≥ 66 years without a history of receipt of dialysis or 
kidney transplantation in the previous 3 years, admitted to a hospital 
for a non-urgent, elective surgical procedure.   
 
We will group these individuals into ACEi or ARB users (exposure 
group) and non-users (control group) and follow them in the 
perioperative period. The incidence of AKI-D in ACEi or ARB 
users and non-users will be determined. 
 
Primary outcome:  
AKI-D (1 to 14 days after surgery) 
 
Secondary outcome:  
Death (1 to 90 days after surgery) 
List of datasets: 
 
ODB (available from April 1990; required from September 1994 to November 
2010) 
Population 
 Age 66+  
 
RPDB (required from January 1992 to March 2011) 
 
CIHI-DAD (available from April 1988; required from January 1992 to March 2011) 
Source 
       Inpatient 
 Same day surgery 
Institution types 
 Acute care (insttype = ‘AP’ or ‘AT’) 
Include suspected/questionable diagnoses? 
 No 
 
OHIP (available from July 1991; required from January 1992 to March 2011) 
Claim Type 
 All 
Code Types 
 Fee codes  
 Diagnosis codes  
  
Defining the cohort 
Index date 
 
Date of elective, non-urgent surgical procedure during a hospital 
admission. If no procedure date is attributed to CIHI-DAD procedural 
code, use the date for hospital admission as ‘index date’ (The date of 
surgery may be less accurate prior to 1999 as some dates were 
missing). 
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Begin with the index date between accrual start date and end date 
(January 1, 1995 to November 30, 2010) 
Surgical  
groups 
Only include hospital admissions with evidence of a surgery in one of 
the following five categories:  
Cardiac surgery (Category C),  
Thoracic surgery (Category T),  
Vascular surgery (Category V),  
Abdominal surgery (Category A),  
Retro-peritoneal surgery (bladder, ureter, kidney) (Category R) 
 
Study period 
 Prior to 2002 fiscal year  Include ICD-9/CCP codes  
 From 2002 fiscal year and onwards  Include ICD-10/CCI codes 
 
We are not studying the following surgical categories: anorectal, 
breast, external head and neck, lower urological and gynecological, 
musculoskeletal, neurosurgical, ophthalmologic, skin and soft tissue, 
unclassified. 
Exclusions  
• Exclude hospital admissions for patients undergoing 
emergent/urgent surgery, also exclude invalid and newborns  
Coded as “urgent”:  code = admcat “U” 
Coded as “emergent”: code = admcat “E” 
Coded as “newborn”: code = admcat “N” 
Coded as “invalid”: code = admcat “Z” 
 
These codes are attached to the hospital admission (and not to a 
given procedure). As such, they will exclude all surgeries done 
during the course of a non-surgical hospital admission (i.e. patient 
admitted to a hospital for reasons other than surgery and surgeries 
performed in this setting are likely to be urgent / emergent). We 
expect that there will be few such surgeries.  
 
• For the years 2006 to 2008 (January 1, 2006 to December 31, 
2008): Exclude all admissions at hospital number 1444 (St. 
Michael’s hospital). 
 
In internal analysis, we observed that there was a far higher than 
expected percentage of surgical patients requiring post-operative 
dialysis at St. Michael’s hospital between 2006 and 2008. We feel 
that this may be due to erroneous use of the dialysis codes for 
cardiopulmonary bypass and have thus chosen to exclude all hospital 
admissions at St. Michael’s hospital during this time-period. Absolute 
numbers were similarly high and falsely elevated the overall rate of 
acute dialysis in Ontario. 
61 
 
 
 
Unless otherwise stated, the following applies: 
Diagnosis type (dxtype) 
 All (alldx) 
 
Include suspected/questionable diagnoses? 
 No 
 
Include abandoned procedures? 
 No 
 
Exclusions: 
• Exclude hospital admissions with invalid or missing IKN 
(ICES key number), age, or sex  
 
• Exclude those deaths prior to the ‘index date’ (this does 
not include the index date)  
 
Reference date 
 Do not include index date in look-back period (stop at 
index-1) 
 
• Exclude hospital admissions where a patient’s age < 66 
years at the time of ‘index date’ (this includes the index 
date) 
 
• Exclude hospital admissions associated with non-Ontario 
residents  
 
• Exclude those patients who do not meet the following 
criteria: evidence of at least one ODB prescription ≤ 120 
days prior to ‘index date’(this does not include the index 
date) 
 
Reference date 
 Do not include index date in look-back period (stop at 
index-1) 
 
• Exclude hospital admissions for patients with evidence of 
dialysis or kidney transplantation in a 3 year look-back 
period prior to the ‘index date’ [this does not include the 
index date] 
 
Study period 
 Prior to 2002 fiscal year  Include ICD-9/CCP/OHIP 
fee codes 
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 From 2002 fiscal year and onwards  Include ICD-
10/CCI/OHIP fee codes 
 
Reference date 
 Do not include index date in look-back period (stop at 
index-1) 
 
• Exclude those patients who are on any of the following 
antihypertensive medications 120 days prior to index date 
[this does not include the index date]:  
 
a) Alpha adrenergic blocker 
b) Adrenergic neurone blocker  
c) Centrally acting anti-adrenergic drug 
d) Vasodilator anti-hypertensive drug 
e) Direct renin inhibitor 
f) Potassium sparing diuretic  
g) Alpha 2-agonist 
 
Reference date 
 Do not include index date in look-back period (stop at 
index-1) 
 
• For patients with multiple eligible surgical procedures 
within study period (after applying previous exclusion 
criteria), select one surgical procedure at random. Exclude 
remaining surgical procedures. 
 
Exposure and control group 
ACEi or 
ARB users 
(exposure 
group) 
≥ 1 ODB prescription for ACEi or ARB ≤ 120 days prior to the index 
date (this does not include the index date).  
Reference date 
 Do not include index date in look-back period (stop at index-1) 
Non-users 
(control 
group) 
No evidence of an ODB prescription for ACEi or ARB ≤ 120 days 
prior to the index date (this does not include the index date). 
Reference date 
 Do not include index date in look-back period (stop at index-1) 
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Time Frame Definitions 
 
Accrual start and 
end dates 
January 1, 1995 to November 30, 2010 
Maximum follow-
up date 
90 days after index date (February 28, 2011) 
Reference date 
 Do not include index date in look-forward period (start at 
index+1) 
When does 
observation 
window terminate? 
Whichever comes first: a) death; or b) 90 days after index date 
Reference date 
 Do not include index date in look-forward period (start at 
index+1) 
Look-back 
window(s) from 
index date 
3 years for comorbid conditions 
120 days for ODB medications 
Reference date 
 Do not include index date in look-back period (stop at 
index-1) 
 
Baseline characteristics for ACEi or ARB users and non-users 
Report standardized difference in baseline characteristics between ACEi or ARB 
users and non-users 
 
Diagnosis type (dxtype) 
 All (alldx) 
 
Study period 
 Prior to 2002 fiscal year  Include ICD-9/CCP/OHIP fee codes  
 From 2002 fiscal year and onwards  Include ICD-10/CCI/OHIP fee codes  
 
Include suspected/questionable diagnoses? 
 No 
 
Demographics 
1. Age at index date (years): median (interquartile range) 
2. Age group categories (66 to 70, 71 to 75, 76 to 80, 81 to 85, 86 to 90, > 90): 
total number (percentage) 
3. Female: total number (percentage) 
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Comorbidities (report total number (percentage)) 
4. Chronic obstructive pulmonary disease (COPD)  
5. Cerebrovascular disease  
6. Peripheral vascular disease (PVD)  
7. Coronary artery disease (CAD) including angina  
8. Congestive heart failure (CHF)  
9. Chronic kidney disease (CKD)  
10. Chronic liver disease  
 
Medication Use (below mentioned medications from 11 to 17; report total number 
(percentage)) 
Users: Evidence of at least one ODB prescription in the 120 days prior to index 
date;   
Non-users: No ODB prescription in the past 120 days prior to index date 
 
Reference date 
 Do not include index date in look-back period (stop at index-1) 
 
11. Oral hypoglycemic (any drug from the following drugs): Sulfonylurea, 
meglitinide, biguanide, thiazolidinedione, alpha-glucosidase inhibitor 
12. Insulin 
13. Antidiabetic medications (oral hypoglycemic & insulin)   
14. Beta-blocker 
15. Calcium channel blocker (CCB)  
16. Non-potassium sparing diuretic 
17. Statin 
  
Surgical Characteristics (report total number (percentage)) 
 
Type of Surgery: 
1. Cardiac surgery (Category C)  
2. Thoracic surgery (Category T)  
3. Vascular surgery (Category V)  
4. Abdominal surgery (Category A)  
5. Retro-peritoneal surgery (bladder, ureter, kidney) (Category R) 
 
Era of surgery: 1995 to 1998, 1999 to 2001, 2002 to 2004, 2005 to 2007, and 2008 
to 2010) (If no procedure date is attributed to CIHI-DAD procedural code, use the 
hospital admission date as ‘index date’ to determine year of cohort entry) 
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Outcomes (events) for incidence analysis 
Report the following outcomes: 
 
1. “Acute Dialysis (AKI-D)” within 14 days of index surgery (Primary 
outcome): Evidence of ≥ 1 OHIP code for acute dialysis within 1 to 14 days 
after index date (acute dialysis outcome must appear during any hospital 
stay).  
Reference date 
 Do not include index date in look-forward period (start at index + 1) 
 
2. Death within 1 to 90 days after index surgery (Secondary outcome) 
Reference date 
 Do not include index date in look-forward period (start at index + 1) 
 
Statistical Analysis 
Association between ACEi or ARB use (exposure) and study outcomes: 
- Use logistic regression model 
- Exposure group: ACEi or ARB users; Referent group: non-users   
- Analysis will be done for (1) Primary outcome; and (2) Secondary outcome 
- Report number of events, unadjusted odds ratio (95% confidence interval 
(CI)) and adjusted odds ratio (95% CI) 
 
Adjust for the following characteristics: 
1. Age (in years) 
2. Sex (male/female; referent=female) 
3. Chronic obstructive pulmonary disease (yes/no; referent=no) 
4. Cerebrovascular disease (yes/no; referent=no) 
5. Peripheral vascular disease (yes/no; referent=no) 
6. Coronary artery disease including angina (yes/no; referent=no) 
7. Congestive heart failure (yes/no; referent=no) 
8. Chronic kidney disease (yes/no; referent=no) 
9. Chronic liver disease (yes/no; referent=no) 
10. Antidiabetic medications use (yes/no; referent=no) 
11. Beta-blocker use (yes/no; referent=no) 
12. Calcium channel blocker use (yes/no; referent=no) 
13. Non-potassium sparing diuretic use (yes/no; referent=no) 
14. Statin use (yes/no; referent=no) 
15. Type of surgery (Categories: C, T, V, A, R; referent surgical category=A) 
16. Era of surgery (1995 to 1998, 1999 to 2001, 2002 to 2004, 2005 to 2007, 
2008 to 2010; referent=1995 to 1998)  
Propensity score matching: Baseline characteristics for ACEi or ARB users and 
non-users (Report standardized difference in baseline characteristics between both 
these groups) 
  
Hard match (1:1) on the following characteristics: 
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1. Age (± 5 years) 
2. Sex (male/female) 
3. Chronic kidney disease (yes/no) 
 
Perform propensity score matching on all the 16 predefined characteristics included 
in the primary analysis using a caliper of ± 0.2 standard deviation of all the 
propensity scores that we derived from all the 16 predefined characteristics. Each 
non-user could only be selected once to derive the propensity score. 
Analysis based on propensity score matching: Association between ACEi or ARB 
use and outcomes.  
- Use logistic regression model 
- Analysis will be done for (1) Primary outcome; and (2) Secondary outcome 
- Report number of events and odds ratio (95% CI) 
Subgroup Analysis:  
Effect modification by (1) Chronic kidney disease (yes/no); (2) Era of surgery 
(1995 to 1998, 1999 to 2001, 2002 to 2004, 2005 to 2007, 2008 to 2010); and (3) 
Type of surgery (cardiac, thoracic, vascular, abdominal, retro-peritoneal)  
 
- Perform for primary and secondary outcomes 
- Use logistic regression model to perform subgroup analyses 
- Adjust for all the predefined characteristics included in the primary analysis 
except the subgroup factor being tested 
- Report total number of events and event rate per 10,000 persons followed by 
unadjusted odds ratio (95% CI) and adjusted odds ratio (95% CI) 
Report p-value for the test of effect modification for all the three characteristics 
mentioned above 
Time to event analysis: Perform only for the primary outcome of acute dialysis 
(AKI-D), censored for (1) death; and (2) end of 14th day after index date 
 
Reference date 
 Do not include index date in look-forward period (start at index + 1) 
 
- Use a Cox proportional hazards model  
- Report number of events, unadjusted hazard ratio (95% CI), and adjusted 
hazard ratio (95% CI) 
- Adjust for all 16 predefined characteristics included in the primary analysis  
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Appendix B: STROBE66 checklist 
 Item 
No 
Recommendation 
Reported on Page 
no., Appendix, 
Figure, or Table 
 Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title or the abstract ii, iii 
(b) Provide in the abstract an informative and balanced summary of what was done and 
what was found 
iii 
Introduction  
Background/rationale 2 Explain the scientific background and rationale for the investigation being reported 1-4, 18, 19 
Objectives 3 State specific objectives, including any pre-specified hypotheses 19, 20 
Methods  
Study design 4 Present key elements of study design early in the paper 21, Appendix A 
Setting 5 Describe the setting, locations, and relevant dates, including periods of recruitment, 
exposure, follow-up, and data collection 
21-25, Appendix A 
Participants 6 (a) Give the eligibility criteria, and the sources and methods of selection of participants. 
Describe methods of follow-up 
23, 24, Appendix A 
(b) For matched studies, give matching criteria and number of exposed and unexposed 27, 28, Appendix A 
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect 
modifiers. Give diagnostic criteria, if applicable 
25-26, 28, 29 
Appendix A 
Data sources/ 
measurement 
8  For each variable of interest, give sources of data and details of methods of assessment 
(measurement). Describe comparability of assessment methods if there is more than one 
group 
21, 22,  
Appendix A,C,D,E 
Bias 9 Describe any efforts to address potential sources of bias 25-28, Appendix A 
Study size 10 Explain how the study size was arrived at n/a 
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable, describe 
which groupings were chosen and why 
25, 26, Appendix A 
Statistical methods 12 (a) Describe all statistical methods, including those used to control for confounding 26-29, Appendix A 
(b) Describe any methods used to examine subgroups and interactions 28, 29, Appendix A 
(c) Explain how missing data were addressed n/a 
(d) If applicable, explain how loss to follow-up was addressed n/a 
(e) Describe any sensitivity analyses n/a 
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Results  
Participants 13 (a) Report numbers of individuals at each stage of study—e.g., numbers potentially 
eligible, examined for eligibility, confirmed eligible, included in the study, completing 
follow-up, and analysed 
Figure 3 
(b) Give reasons for non-participation at each stage 23, 24, Figure 3 
(c) Consider use of a flow diagram Figure 3 
Descriptive data 14 (a) Give characteristics of study participants (e.g., demographic, clinical, social) and 
information on exposures and potential confounders 
Table 7 
(b) Indicate number of participants with missing data for each variable of interest n/a 
(c) Summarise follow-up time (e.g., average and total amount) 30, 31 
Outcome data 15 Report numbers of outcome events or summary measures over time 30, Table 8 
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their 
precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for 
and why they were included 
Table 8 
(b) Report category boundaries when continuous variables were categorized Table 7 
(c) If relevant, consider translating estimates of relative risk into absolute risk for a 
meaningful time period 
Table 9 
Other analyses 17 Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity 
analyses 
31, 32, Table 10, 
Table 11 
Discussion  
Key results 18 Summarise key results with reference to study objectives 40 
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or 
imprecision. Discuss both direction and magnitude of any potential bias 
44-46 
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, 
multiplicity of analyses, results from similar studies, and other relevant evidence 
40-43 
Generalisability 21 Discuss the generalisability (external validity) of the study results 43-48 
Other information  
Funding 22 Give the source of funding and the role of the funders for the present study and, if 
applicable, for the original study on which the present article is based 
v 
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Appendix C: Codes used to identify comorbidities 
 
Exclusion: Dialysis and kidney transplantation codes 
  Codes Validation  
1. Dialysis ICD-9: “V45.1”, “V56.0”, 
“V56.8” 
 
V45.1, V56.0, V56.8: 
Sensitivity85 = 90.4%; 
Specificity85 = 93.8%;  
PPV85 = 94.0%;   
NPV85 = 90.0% 
ICD10: "T824", "Y602", "Y612", 
"Y622", "Y841", "Z49", "Z992", 
"N180", "E1022", "E1023", 
"E1122", "E1123", "E1322", 
"E1323", "E1422", "E1423" 
 
CCP: “51.27”, “51.42”, “51.43”, 
“51.95”, “66.98” 
 
CCI: "1OT53DATS", 
"1OT53HATS", "1OT53LATS", 
"1PZ21", "1SY55LAFT", 
"7SC59QD", "1KY76" 
 
OHIP FEE: "R850", "G324", 
"G336", "G327", "G862", 
"G865", "G099", "R825", "R826", 
"R827", "R833", "R840", "R841", 
"R843", "R848", "R851", "Z450", 
"Z451", "Z452", "G864", "R852", 
"R853", "R854", "R885", "G333", 
"H540", "H740" 
 
    
2. Kidney 
Transplantation 
ICD-9: “V42”  
ICD-10: “N165”, “Z940”, 
“T86100”, “T86101”, “T86102” 
 
CCP: “67.43”, “67.5”  
CCI: “1PC85LAXXJ”, 
"1PC85LAXXK" 
 
OHIP FEE: “E762”, “S435”, 
“E769”, “S434”, “E771”, “Z631”, 
“G347”, “G348”, “G412”, 
“G408”, “G409” 
 
 
Comorbidities  
  Codes Validation 
1. Chronic kidney 
disease (CKD) 
ICD-9: “403.0”, “403.1”, 
“403.9”, “404.0”, “404.1”, 
“404.9”, “582”, “583”, “580”, 
“581”, “584”, “585”, “586”, 
583 to 586 (ICD-9) and 
N00, N04, N08, N18, 
N19 (ICD-10): 
Sensitivity83 = 28.3%; 
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“587”, “588.0”, “588.8”, 
“588.9”, “593.7” 
 
Specificity83 = 94.6%; 
PPV83 = 51.9%; 
NPV83 = 86.5%; 
(Case definition for 
CKD: 1 claim or 1 
hospitalization in past 3 
years; compared with the 
reference standard of 
eGFR < 60 
mL/min/1.73m2) 
ICD-10: “I12”, “I13”, “N01”, 
“N03”, “N05”, “N07”, “N14”, 
“N15”, “N00”, “N04”, “N08”, 
“N18”, “N19”, “N26”, “N25”, 
“N137”, “N280”, “N2888”, 
“N06”, “N391” 
 
OHIP DX: “403”, “580”, 
“581”, “585”  
 
    
2. Chronic 
obstructive 
pulmonary 
disease 
ICD-9: "491", "492", "496" 
 
Sensitivity78 = 85.0%; 
Specificity78 = 78.4% 
(Validated for patients > 
35 years) 
ICD-10: "J41", "J42", "J43", 
"J44" 
    
3. Cerebrovascular 
disease  
ICD-9: "430", "432.1", "433", 
"435", “436”, "437", "438", 
"362.3"  
436: PPV82 = 78%  
ICD-10: "I60", "I61",  "I63",  
"I64",  "I65", "I66", "I67", 
"I68", "I69", "G45", "G46", 
"H34"  
I60, I61, I63 to I69, 
G45,G46: 
Sensitivity79 = 89%; 
PPV79 = 93% 
CCP: "50.11", "50.12", "51.28"   
CCI: "1JE50", "1JE57", 
"1JE87", "1JW50", "1JX57", 
"1JW57", "1JW76" 
 
OHIP FEE: "R792", "N220", 
"N223", "J050", "N104", 
"N157", "N120"  
 
OHIP DX: "432", "435", 
"436", "437" 
 
    
4. Peripheral 
vascular disease 
ICD-9: "440.0", "440.2", 
"440.8", "440.9", "557.1", 
"443.9", "444" 
 
ICD-10: "I700", "I702", 
"I708", "I709", "I731", "I738", 
"I739", "K551" 
I739: Sensitivity79 = 
74%; PPV79 = 62%; 
I700, I702, I708, I709, 
I731, I738:  
PPV84 = 100% 
CCP: "51.25", "51.29", 
"50.14", "50.16", "50.18", 
"50.28", "50.38"  
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CCI: "1KG76MI", "1KA76", 
"1KA50", "1KE76", "1KG26", 
"1KG50", "1KG57", "1KG87" 
 
OHIP FEE: "R787", "R780", 
"R797", "R804", "R809", 
"R875", "R815", "R936", 
"R783", "R784", "R785", 
"E626", "R814", "R786", 
"R937", "R860", "R861", 
"R855", "R856", "R933", 
"R934", "R791", "R794", 
"E672", "R813", "R867", 
"E649" 
 
    
5. Coronary artery 
disease 
ICD-9: "412", "414", "429.2", 
"429.5", "429.6", "429.7" 
 
ICD-10: "I20", "I21", "I22", 
"I23", "I24", "I25", "Z955", 
"Z958", "Z959", "R931", 
"T822" 
I21, I22, I25:  
Sensitivity79 = 86%, 
PPV79 = 96%; 
I20: Sensitivity80 = 82%; 
PPV80 = 52%; 
I23: PPV84 = 98% 
CCP: "48.01", "48.02", 
"48.03", "48.04", "48.05", 
"48.1", "48.2", "48.3" 
 
CCI: "1IJ26", "1IJ27", "1IJ50", 
"1IJ54", "1IJ57", "1IJ76"  
 
OHIP FEE: "R741", "R742", 
"R743", "G298", "E646", 
"E651", "E652", "E654", 
"E655", "G262", "Z434", 
"Z448"  
 
OHIP DX: "410", "412", "413" 410:  
Sensitivity77 = 88.8%;  
Specificity77 = 92.8%;  
PPV77 = 88.5% 
 
413:  
Sensitivity77 = 57.9%; 
Specificity77 = 93.9%;  
PPV77 = 78.1% 
    
6. Congestive heart 
failure 
ICD-9: "425", "518.4", "514"  
ICD-10: "I255", "I500", 
"I501", "I509", "J81" 
I500, I501:  
Sensitivity79 = 86%;  
PPV79 = 86%; 
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CCP: "49.61", "49.62"  
CCI: "1HP53"   
OHIP FEE: "R701", "R702"  
OHIP DX: "428" 428:  
Sensitivity77 = 58.5%; 
Specificity77 = 96.8%; 
PPV77 = 65.1% 
    
7. Chronic liver 
disease 
ICD-9: "571.0", "571.1", 
"571.2", "571.3", "571.5", 
"571.6", "070.2", "070.3", 
"070.4", "070.5", "V02.6" 
PPV81 = 43 to 93%;  
NPV81 = 77 to 100%; 
 
ICD-10: "K73", "K702", 
"K703", "K717", 
"K740","K742", "K743", 
"K744", "K745", "K746", 
"K721", "K729", "K766", 
"K767" 
K73, K702, K703, K717, 
K740, K742, K743, 
K744, K745, K746:  
Sensitivity79 = 58%;  
PPV79 = 69%; 
 
K721, K729, K766, 
K767:  
Sensitivity79 = 86%;  
PPV79 = 63%;  
 
ICD-9: International classification of disease 9th version; ICD-10: International classification of disease 
10th version; CCI: The Canadian Classification of Health Interventions; CCP: The Canadian Classification 
of Diagnostic, Therapeutic and Surgical Procedures; OHIP FEE – Ontario health insurance plan fee codes; 
OHIP DX: Ontario health insurance plan diagnostic codes;   
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Appendix D: OHIP fee codes for acute dialysis (AKI-D) 
 
R849 Dialysis - haemodialysis - initial & acute 
G323 Dialysis - haemodialysis - acute, repeat (first 3 services) 
G866 Intermittent haemodialysis treatment centre 
G330 Peritoneal dialysis - acute (up to 48 hours) 
G331 Peritoneal dialysis - repeat acute (up to 48 hours) (first 3 services) 
G093 Haemodiafiltration - continuous - initial & acute (first 3 services) 
G095 Slow continuous ultrafiltration - initial & acute (first 3 services) 
G294 Arteriovenous slow continuous ultrafiltration - initial and acute  
(first 3 services) 
G295 Continuous arteriovenous haemofiltration - initial and acute  
(first 3 services) 
OHIP fee codes – Ontario health insurance plan fee codes 
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Appendix E: Sample of codes used to determine surgical procedures  
  
SURGERY 
CLASS 
DATABASE SAMPLE OF CODES USED 
Cardiac 
CIHI- 
procedure 
CCI: 1IJ76 (Bypass, coronary arteries), 
1HU80 (Repair, mitral valve) 
CIHI- 
procedure 
CCP: 47.22 (Replacement of mitral valve with tissue 
graft), 48.09 (Other removal of coronary artery 
obstruction) 
 
Thoracic 
CIHI- 
procedure 
CCI: 1GV87 (Excision partial, pleura), 1GR91 
(Excision radical, lobe of lung),  
CIHI- 
procedure 
CCP: 54.0 (Esophagotomy), 44.5 (Complete 
pneumonectomy) 
Vascular 
CIHI- 
procedure 
CCI: 1KE76 (Bypass, abdominal arteries), 1JK57 
(Extraction, subclavian artery) 
CIHI- 
procedure 
CCP: 50.14 (Endarterectomy of aorta), 50.34 
(Resection of aorta with replacement) 
  
Abdominal 
CIHI- 
procedure 
CCI: 1NM80LA (Repair, large intestine open 
approach using apposition technique), 1NF87RK 
(Excision partial, stomach with vagotomy open 
approach gastrojejunal anastomosis) 
CIHI- 
procedure 
CCP: 53.51 (Excision of accessory spleen), 57.55 
(Left hemicolectomy) 
Retro-
peritoneal 
CIHI- 
procedure 
CCI: 1PG80 (Repair, ureter), 
1PB87 (Excision, partial, adrenal gland)  
CIHI- 
procedure 
CCP: 69.4 (Partial cystectomy), 20.2 (Bilateral 
adrenalectomy) 
 
CCI: The Canadian Classification of Health Interventions; CCP: The Canadian Classification of 
Diagnostic, Therapeutic and Surgical Procedures; CIHI-DAD: Canadian Institute for Health Information 
Discharge Abstract Database;  
Juurlink et al.80 performed a CIHI-DAD validation study and observed a high sensitivity 0.95 
(interquartile range (IQR): 0.89 to 0.99), and positive predictive value 0.91 (IQR: 0.82 to 0.97) to identify 
surgical procedures using CCI codes. The CIHI-DAD considers CCP prior to 2002 and CCI thereafter to 
identify surgical procedures. 
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